

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
WO 2004/006678 A1

(51) International Patent Classification<sup>7</sup>: A01N 47/40,  
C12N 5/08, 5/10, 15/63, C07H 21/02, 21/04, C12P 19/34

Weizensteinerstr.14, 5020 Salzburg (AT). BAUER, Johann  
[AT/AT]; Reisenbergerstr. 18, 5023 Salzburg (AT).

(21) International Application Number:  
PCT/US2003/022469

(74) Agents: SEIDE, Rochelle, K. et al.; Baker Botts, L.L.P.,  
30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(22) International Filing Date: 17 July 2003 (17.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/198,447 17 July 2002 (17.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): IN-  
TRONN, INC. [US/US]; 910 Clopper Road, Suite 210,  
Gaithersburg, MD 20878 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MITCHELL,  
Lloyd, G. [US/US]; 4519 Greta Street, Bethesda,  
MD 20814 (US). PUTTARAJU, Madaiah [IN/US];  
12115 Stardrift Drive, Germantown, MD 20876 (US).  
DALLINGER, Guenter [AT/AT]; Am Winklgarten 27,  
4030 Linz (AT). KLAUSEGGER, Alfred [AT/AT];

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SPLICEOSOME MEDIATED RNA TRANS-SPLICING FOR CORRECTION OF SKIN DISORDERS

(57) Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA traps-splicing. The compositions of the invention include pre-traps-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a traps-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention can be genetically engineered to interact with a specific target premRNA expressed in cells of the skin so as to result in correction of genetic defects responsible for a variety of different skin disorders to encode a reporter molecule or protein that may have therapeutic value. The compositions of the invention further include recombinant vectors capable of expressing the PTMs of the invention and cells expressing said PTMs. The methods of the invention encompass contacting the PTMs of the invention with specific target pre-mRNA expressed within cells of the skin under conditions in which a portion of the PTM is traps-spliced to a portion of the target pre-mRNA to form a chimeric RNA molecule wherein the genetic defect in the specific gene has been corrected. The present invention is based on the successful *trans*-splicing of the collagen XVII pre-mRNA thereby establishing the usefulness of *trans*-splicing for correction of skin specific genetic defects. The methods and compositions of the present invention can be used in gene therapy for treatment of specific disorders of the skin, *i.e.*, genodermatoses, such as epidermal fragility disorders, keratinization disorders, hair disorders and pigmentation disorders as well as cancers of the skin.

WO 2004/006678 A1

SPLICEOSOME MEDIATED RNA *TRANS*-SPLICING  
FOR CORRECTION OF SKIN DISORDERS

SPECIFICATION

RELATED APPLICATION

- 5                    This application claims priority to United States Application No. 10,198,447 filed on June 20, 2002, and is incorporated by reference.

1. INTRODUCTION

- The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA
- 10    *trans*-splicing. The compositions of the invention include pre-*trans*-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a *trans*-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention are genetically engineered to interact with a specific
- 15    target pre-mRNA expressed in cells of the skin so as to result in correction of genetic defects responsible for a variety of different skin disorders. The compositions of the invention further include recombinant vectors systems capable of expressing the PTMs of the invention and cells expressing said PTMs. The methods of the invention encompass contacting the PTMs of the invention with specific target pre-mRNA
- 20    expressed within cells of the skin under conditions in which a portion of the PTM is *trans*-spliced to a portion of the target pre-mRNA to form a chimeric RNA molecule wherein the genetic defect in the specific gene has been corrected. The present invention is based on the successful *trans*-splicing of the collagen XVII pre-mRNA thereby establishing the usefulness of *trans*-splicing for correction of skin specific
- 25    genetic defects. The methods and compositions of the present invention can be used in gene therapy for treatment of specific disorders of the skin, *i.e.*, genodermatoses, such as epidermal fragility disorders, keratinization disorders, hair disorders and pigmentation disorders as well as proliferative disorders of the skin such as cancer and psoriasis of the skin.

## 2. BACKGROUND OF THE INVENTION

Significant progress has recently been made towards better understanding the genetic basis of heritable skin disorders. An understanding of the underlying mutations responsible for specific skin disorders has provided the basis for cutaneous gene therapy. Because of the easy accessibility of skin and the fact that skin cells, such as keratinocytes and dermal fibroblasts, can be easily grown in culture, the skin provides an ideal tissue for gene therapy.

Epidermolysis bullosa (EB) is the term applied to a heterogeneous group of inherited skin disorders in which minor trauma leads to blistering of skin and mucous membranes. Depending on the level of tissue cleavage, EB can be divided into three main groups: (i) EB simplex with blister formation occurring in the basal keratinocyte, (ii) junctional EB (JEB) with blister formation in the lamina lucida and (iii) EB dystrophicans with blister formation below the lamina densa.

JEB patients are divided into two main groups, Herlitz JEB and generalized atrophic benign EB (GABEB). Patients diagnosed with the former disease usually die within their first year of life, whereas the latter diagnosis is associated with a better prognosis and a tendency for improvement during life. Initial observations describing reduced expression of bullous pemphigoid antigen 2 (BPAG2), identified as type XVII collagen, in patients suffering from GABEB were followed by the identification of mutations in the gene coding for BPAG2 (Col17A1). To date, a number of different mutations in the Col17A1 have been identified leading to the establishment of a mutation database, which has facilitated the analysis of the effects of specific mutations on the clinical presentation of nH-JEB. For example, it has been determined that stop codon mutations or mutations leading to downstream stop codons on both alleles are associated with the original "GABEB" phenotype.

In addition, EB simplex with late onset muscular dystrophy (EBS-MD) patients have been characterized with mutations in the plectin gene. Some of these patients feature compound heterozygosity for a three base-pair insertion at position 1287 (1287ins3) leading to the insertion of leucine as well as missense mutation, Q1518X causing the insertion of a stop codon in the plectin coding region (Bauer, JW *et al.*, 2001 *Am J Pathol* 158: 617-625).

In skin gene therapy, most efforts to date have attempted to deliver full length cDNA copies of the affected gene using retroviral vectors. However, the delivery of full length cDNA in skin therapy is often limited by the size of the mRNA (or cDNA), for example, the plectin mRNA is 14.8 kb, the type VII collagen mRNA is 9.2 kb and the type XVII collagen mRNA is 6.5 kb. The size of these genes, mutated in patients with various forms of EB, and their regulatory elements are beyond the capacity of delivery systems suitable for skin gene therapy using retroviral or adeno-associated viral vectors. Therefore, it would be advantageous to reduce the size of the therapeutic sequence that has to be delivered.

It is also critical that the genes implicated in cutaneous blistering disorders and targeted for gene therapy are only expressed by keratinocytes of a specific epidermal layer. For example, ectopic expression of such genes may lead to disordered epithelial polarity. One possible way to address the problem of keratinocyte specific expression is to use specific regulatory elements to direct transgene expression. However, the use of such promoters further increases the size of the insert in a therapeutic vector.

For the Col17A1 gene, alternative approaches to gene correction have been described. Notably, there are natural mechanisms by which mutations have been corrected in the Col17A1 gene validating the concept of gene therapy. For example, Jonkman *et al.*, (1997, *Cell* 88:543-551) reported on a patient who had patches of normal appearing skin in a symmetrical leaf-like pattern on the upper extremities. The underlying mutations in the Col17A1 gene had been identified as R1226X paternally, and 1706delA, maternally. In the clinical unaffected areas of the skin about 50% of the basal cells were expressing type XVII collagen at a reduced level due to a mitotic gene conversion surrounding the maternal mutation, thus leading to loss of heterozygosity in this area. These observations suggest that expression of less than 50% of full length type XVII collagen is sufficient to correct the phenotypic expression of nH-JEB. In addition, a partly successful gene correction by the keratinocyte splicing machinery has been described in patients with the homozygous R785X mutation in the Col17A1 gene (Ruzzi L *et al.*, 2001 *J. Invest Dermatol* 116:182-187). In these patients, the exclusion of exon 33, harboring the mutation,

leads to an unusual mild phenotype, although there is only 3-4% of detectable type XVII collagen protein. Similar in frame skipping of exons has also been reported for patients with mutations in the Col17A1 and LAMB3 gene.

Until recently, the practical application of targeted *trans*-splicing to  
5 modify specific target genes was limited to group I ribozyme-based mechanisms. Using the *Tetrahymena* group I ribozyme, targeted *trans*-splicing was demonstrated in *E. coli*. (Sullenger B.A. and Cech. T.R., 1994, *Nature* 341:619-622) , in mouse fibroblasts (Jones, J.T. *et al.*, 1996, *Nature Medicine* 2:643-648), human fibroblasts (Phylactou, L.A. *et al.*, 1998 *Nature Genetics* 18:378-381) and human erythroid  
10 precursors (Lan *et al.*, 1998, *Science* 280:1593-1596). While many applications of targeted RNA *trans*-splicing driven by modified group I ribozymes have been explored, targeted *trans*-splicing mediated by native mammalian splicing machinery, *i.e.*, spliceosomes, is now being actively developed.

Spliceosomal mediated *trans*-splicing utilizes the endogenous cellular  
15 splicing machinery to repair inherited genetic defects at the RNA level by replacing mutant exon or exons. The use of such techniques has a number of advantages over the conventional gene therapy approaches. For example, the repaired product is always under endogenous regulation and correction will only occur in cells endogenously expressing the target pre-mRNA. In addition, genetic diseases can be  
20 corrected regardless of the mode of inheritance. Finally, the use of *trans*-splicing reduces the size of the transgene into an expression vector.

U.S. Patent Nos. 6,083,702, 6,013,487 and 6,280,978 describe the use of PTMs to mediate a *trans*-splicing reaction by contacting a target precursor mRNA to generate novel chimeric RNAs. The present invention provides specific PTM  
25 molecules designed to correct specific defective genes expressed within cells of the skin and associated with skin disorders. The specific PTMs of the invention may be used to treat a variety of different skin disorders such as genodermatoses including but not limited to epidermal fragility disorders, keratinization disorders, hair disorders, pigmentation disorders and cancer disorders.

30

### 3. SUMMARY OF THE INVENTION

The present invention relates to compositions and methods for generating novel nucleic acid molecules through spliceosome-mediated targeted *trans*-splicing. In particular, the compositions of the invention include pre-*trans*-splicing molecules (hereinafter referred to as "PTMs") designed to interact with a specific target pre-mRNA molecule expressed within cells of the skin (hereinafter referred to as "skin cell specific pre-mRNA") and mediate a spliceosomal *trans*-splicing reaction resulting in the generation of a novel chimeric RNA molecule (hereinafter referred to as "chimeric RNA"). Skin specific pre-mRNA molecules include, but are not limited to, those transcribed from the collagen genes, *i.e.*, type VII collagen, type XVII collagen (Col17A1), laminin and plectin genes to name a few. The invention is based on the successful targeted *trans*-splicing of the endogenous Col17A1 pre-mRNA in keratinocytes of the skin, however, the methods and compositions of the invention may also be used to target defective genes in other types of skin cells, *i.e.*, fibroblasts, melanocytes, dermal papilla cells, nerve cells and blood cells.

The compositions of the invention include PTMs designed to interact with a skin specific target pre-mRNA molecule and mediate a spliceosomal *trans*-splicing reaction resulting in the generation of a novel chimeric RNA molecule. Such PTMs are designed to correct genetic defects in a skin specific gene. The general design, construction and genetic engineering of PTMs and demonstration of their ability to successfully mediate *trans*-splicing reactions within the cell are described in detail in U.S. Patent Nos. 6,083,702, 6,013,487 and 6,280,978 as well as patent Serial Nos. 09/756,095, 09/756,096, 09/756,097 and 09/941,492, the disclosures of which are incorporated by reference in their entirety herein.

The methods of the invention encompass contacting the PTMs of the invention with a skin cell specific target pre-mRNA under conditions in which a portion of the PTM is *trans*-spliced to the target pre-mRNA to form a novel chimeric RNA. The methods of the invention comprise contacting the PTMs of the invention within a cell expressing a skin cell specific target pre-mRNA under conditions in which the PTM is taken up by the cell and a portion of the PTM is *trans*-spliced to a portion of the target pre-mRNA to form a novel chimeric RNA molecule that results

in correction of a skin cell specific genetic defect. Alternatively, nucleic acid molecules encoding PTMs may be delivered into a target cell followed by expression of the nucleic acid molecule to form a PTM capable of mediating a *trans*-splicing reaction. The PTMs of the invention are genetically engineered so that the novel  
 5 chimeric RNA resulting from the *trans*-splicing reaction encodes a protein that complements a defective or inactive skin cell specific protein within the cell. The methods and compositions of the invention can be used in gene repair for the treatment of various skin disorders, such as epidermolysis bullosa.

#### 10 4. BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic representation of different *trans*-splicing reactions. (a) *trans*-splicing reactions between the target 5' splice site and PTM's 3' splice site, (b) *trans*-splicing reactions between the target 3' splice site and PTM's 5' splice site and (c) replacement of an internal exon by a double *trans*-splicing reaction  
 15 in which the PTM carries both 3' and 5' splice sites. BD, binding domain; BP, branch point sequence; PPT, polypyrimidine tract; and ss, splice sites.

Figure 2A-D. Schematic representation of Col17A1 model constructs. Detailed structure of (Figure 2A) the COL17A1-lacZ target (lacZ-T1) for the  $\beta$ -gal model-system and of (Figure 2B) the Col17A1 mini-gene target (T2). The relative  
 20 position of primers lac9F, KI-3R and KI-5R are indicated. (Figure 2C) Schematic diagram of a PTM for the  $\beta$ -gal test-system. (1; 2; 3) Detailed structures and sequences of the PTM1, 3 and 5 binding domains, respectively. (Figure 2D) Schematic diagram of PTMs used in the Col17A1 mini-gene system (1; 2; 3). Detailed structures and sequences of the PTM2, 4 and 6 binding domains,  
 25 respectively. Abbreviations: BP; branch point, PPT: polypyrimidine tract, ss: 5' and 3' splices sites, BD: binding domain

Figure 3A-C. The  $\beta$ -gal test-system shows accurate *trans*-splicing at the RNA level and restoration of  $\beta$ -gal protein function in 293T cells using Col17A1 intron 51 as a target. Figure 3A. Demonstration of *cis*- and *trans*-splicing in 293T  
 30 cells using the  $\beta$ -gal test-system. One representative experiment of 5 experiments is shown. 30 ng and 300 ng of total RNA were used for the detection of *cis*- (left panel)

or *trans*-splicing (right panel), respectively. Lane 1: Transfection experiment with vector alone. Lane 2: Transfection of LacZ-T1 alone. Lanes 3, 4, 5: Transfection of PTM1, 3 and 5 alone. Lane 6, 7, 8: Co-transfection of 2  $\mu$ g LacZ-T1 and 2  $\mu$ g of either PTM1, 3 or 5. Lane M: 100 bp DNA size marker. Figure 3B. Upper panel: DNA sequence of *cis*-spliced lacZ-T1 target mRNA showing the correct splicing between the 5' and 3' exon and two in frame stop codons (underlined). The splice junction is indicated by an arrow. Lower panel: DNA sequence of *trans*-spliced mRNA showing the accurate *trans*-splicing and replacement of the stop codons. Figure 3C. Restoration of  $\beta$ -gal activity is increased with respect to the length of the binding domain.  $\beta$ -gal activity representing the average of four independent transfection experiments. Lysates from 293T cells transfected with 2  $\mu$ g of LacZ-T1, PTM3 and PTM5 alone, respectively or co-transfected with 2  $\mu$ g target (LacZ-T1) and 2  $\mu$ g of PTM; LacZ-T1 + PTM1: 95.73 U/mg (+ SD 30 U/mg) protein; LacZ-T1 + PTM3: 117.52 U/mg (+ SD 30 U/mg) protein. LacZ-T1 + PTM5: 328.94 U/mg (+ SD 50 U/mg) protein. (SD = standard deviation).

Figure 4. Efficient and accurate *trans*-splicing between LacZ-T1 pre-mRNA and PTM5 RNA produces functional  $\beta$ -gal in epithelial 293T cells, in human keratinocytes and a GABEB cell-line *in vitro*. 293T cells (uppermost panel), human primary keratinocytes (middle panel) and a GABEB cell-line (lowest panel) were transfected with pcDNA3.1 vector (control), or co-transfected with LacZ-T1 + PTM5. 25% of transfected 293T cells showed restoration of  $\beta$ -gal expression; while  $\beta$ -gal activity was restored in 5% of primary keratinocytes and the GABEB keratinocyte cell line. No  $\beta$ -gal activity was detected in the control cells.

Figure 5A-B. *Trans*-splicing between the T2 mini-gene pre-mRNA and pCol17-PTM's containing the cDNA sequence spanning exons 52 to 56 in 293T cells. Figure 5A. Upper panel; Lane 1: Mock transfection with pcDNA3.1 vector. Transfection of either T2 or PTM2, PTM4 and PTM6 alone, showing correct *cis*-splicing of the target pre-mRNA in Lane 2 and the absence of *cis*-splicing products for all PTM's when transfected alone (lanes 3, 4 and 5), respectively. Lanes 6, 7 and 8 are showing co-transfection experiments of T2 and PTM2, PTM4, and PTM6 producing a fragment of the predicted length (568 bp) Lane M; 100 bp DNA size marker. Lower



panel: Lane 1: Mock transfection experiment with pcDNA3.1 vector. RT-PCR fragments of *trans*-spliced product (574 bp) can be obtained from RNA prepared from co-transfection experiments using T2 as a target and either PTM2, PTM4, or PTM6 (Lanes 6, 7 and 8), respectively. Transfections of either T2 or PTM2, PTM4, and  
 5 PTM6 alone showed no *trans*-splicing (Lanes 2, 3, 4 and 5). Lane M: 100 bp DNA size marker. Figure 5B. Schematic drawing showing the binding sites of primers used for RT-PCR analysis of mini-gene *cis*- and *trans*-splicing.

Figure 6A. Accurate *trans*-splicing restores  $\beta$ -gal activity in human keratinocytes. Figure 6A-B. Primary keratinocytes (I)  $\beta$ -gal activity in units/mg  
 10 protein in human keratinocytes Lane 1: transfection of pcDNA3.1 vector alone. Lane 2: LacZ-T1 alone. Lane 3: PTM5 alone. Lane 4: Co-transfection of LacZ-T1 and PTM5 revealing a  $\beta$ -gal activity of 190 U/mg protein (+ SD 50 U/mg). (II) RT-PCR analysis of total RNA prepared from the same experiment for *cis*-splicing (left panel) and *trans*-splicing (right panel). Control transfections included vector alone (Lane 1);  
 15 LacZ-T1 alone (Lane 2) and PTM5 alone (Lane 3). Lane 4 shows a RT-PCR product of 298 nt length as predicted for accurate *trans*-splicing between the target and PTM5 (right picture). A 302 nt RT-PCR product is generated in Lane 2 (LacZ-T1 alone) and Lane 4 (LacZ-T1 + PTM5) showing *cis*-splicing of the LacZ-T1 target (left picture).  
 Figure 6B. Immortalized GABEB keratinocytes (I)  $\beta$ -gal activity in units/mg protein  
 20 in the GABEB cell-line. Lane 1: Transfection of pcDNA3.1 vector alone. Lane 2: LacZ-T1 alone. Lane 3: PTM5 alone. Lane 4; Co-transfection of LacZ-T1 and PTM5 revealing  $\beta$ -gal activity of 295.6 U/mg protein (+ SD 60 U/mg). (II) RT-PCR analysis of total RNA prepared from the same experiment for *cis*-splicing (left panel) and *trans*-splicing (right panel). Control transfections included vector alone (Lane 1);  
 25 LacZ-T1 alone (Lane 2) and PTM5 alone (Lane 4). Lane 3 showing the RT-PCR product of 298 nt length as predicted for accurate *trans*-splicing of target and PTM5 (right picture). RT-PCR for *cis*-splicing of LacZ-T1 shows a 302 nt product in lanes 2 (LacZ-T1 alone) and Lane 3 (LacZ-T1 + PTM5) (left picture).

Figure 7. Detection strategy for endogenous *trans*-splicing of the  
 30 Col17A1 pre-mRNA in HaCatKC cells. Therapeutic molecule (PTM5) consists of Col7A1 binding domain 51, spacer element, branch point (BP) and polypyrimidine

tract (PPT) followed by a functional part of  $\beta$ -galactosidase lacZ 3' exon cloned into pcDNA3.1(-). This construct was transfected into HaCat cells. Pre-mRNA resulted in correct endogenously *trans*-spliced product of a genomic fragment spanning exon 1-51 and LacZ 3' exon confirmed by semi-nested RT-PCR with primer 51-1F, lac6R and lac4R.

Figure 8. Endogenous *trans*-splicing of Col17A1 pre-mRNA with PTM5. Sequence of correct endogenously *trans*-spliced product showing the splice junction between exon 51 with lacZ 3' exon (A) and confirmation by restriction digestion of 226bp RT-PCR product with MseI resulting in two fragments of 168bp and 58bp (B).

Figure 9. Schematic of 5' *trans*-splicing LacZ repair model for hereditary diseases.

Figure 10. Target LacZ-T3 containing intron 9 of the plectin gene and lacZ-T4 used for optimizing *trans*-splicing and transfection conditions.

Figure 11. LacZ-PTM3 (intron 9 specific binding domain) and lacZ-PTM4 (non-specific binding domain) for establishing optimal *trans*-splicing conditions.

Figure 12. PLEC-PTM-5 for the introduction of the 1287ins3 mutation in 293T cells.

Figure 13. PLEC-PTM-6 for repair of the 1287ins3 mutation in plectin deficient patient cells.

Figure 14A-E. *Trans*-splicing strategy for COL17A1 Gene.

Figure 14A. PTM6 consists of Col17A1 binding domain 51, spacer element, branch point (BP) and poly pyrimidine tract (PPT) followed by exon 52-56 cloned into pcDNA3.1(-). This construct was transiently transfected into GABEB cells harboring the 4003 del TC mutation.

Figure 14B. Semi-nested RT-PCR with BPAG2 primer 51-1F, 53-1R and 52-1R. RNA was extracted from PTM6 transfected GABEB cells and semi-nested RT-PCR was performed with BPAG2-primer 51-1F, 53-1R and 52-1R. By sequencing the expected 323bp fragment heterozygosity of mutant and corrected alleles could be demonstrated.

Figure 14C. TOPO Cloning +Nla III digestion. For quantification of wildtype vs. mutant DNA in the 323bp fragment, it was cloned into a TOPO vector. 100 clones were analysed by colony PCR and subsequent NlaIII digest, which detects the 4003 del TC mutation in the COL17A1 gene. A given digest profile of 4 different possibilities and fragment sizes is shown.

Figure 14D. Sequencing of mutant and wildtype clones confirmed the correct *trans*-splicing of PTM6 into GABEB cells. Sequencing of mutant and wildtype clones confirmed the correct *trans*-splicing of PTM6 into GABEB cells.

Figure 14E. Analysis of 100 clones revealed 48 clones with correct *trans*-splicing and correction of the mutation 4003 del TC in the COL17A1 gene.

Figure 15. Immunofluorescence of transfected PTM6 into GABEB cells with Lipofectamine Plus.

Figure 16 depicts *trans*-splicing strategy for COL7A1 gene (Dystrophic epidermolysis bullosa). Figure 16A. 3' *trans*-splicing in a LacZ-model system to target intron 72 of the COL7A1 gene. Figure 16 B. Schematic drawing of LacZ-Target1 (T1) containing COL7A1-Intron 72 cloned between LacZ 5' and stop-LacZ 3' in a pcDNA3.1 expression vector. LacZ-PTM consists of BD intron 72 cloned 5' of functional LacZ 3' in a pcDNA 3.1 expression vector.

Figure 17.  $\beta$ -gal Assay of a cotransfection of COL7 target T1 and PTM 8, 9, 10 in 293T cells with Lipofectamin.

Figure 18  $\beta$ -gal staining of COL7PTM transfected human HEK 293T cells. left panel:(a) target +PTM8, (c) target +PTM9, (e) target =PTM10; right panel:corresponding control PTM without target.

## 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compositions comprising *pre-trans*-splicing molecules (PTMs) and the use of such molecules for generating novel nucleic acid molecules. The PTMs of the invention comprise (i) one or more target binding domains that are designed to specifically bind to a skin cell specific target pre-mRNA and (ii) a 3' splice region that includes a branch point and a 3' splice acceptor site and/or a 5' splice donor site. The 3' splice region may further comprise a

polypyrimidine tract. In addition, the PTMs of the invention can be engineered to contain any nucleotide sequences such as those encoding a translatable protein product and one or more spacer regions that separate the RNA splice site from the target binding domain.

5                   The methods of the invention encompass contacting the PTMs of the invention with a skin cell specific target pre-mRNA under conditions in which a portion of the PTM is *trans*-spliced to a portion of the target pre-mRNA to form a novel chimeric RNA that results in correction of a skin cell specific genetic defect. Such skin specific target pre-mRNA molecules include but are not limited to those  
10                   encoding plectin, type XVII collagen, type VII collagen and laminin, to name a few.

#### 5.1 STRUCTURE OF THE PRE-TRANS-SPLICING MOLECULES

                  The present invention provides compositions for use in generating novel chimeric nucleic acid molecules through targeted *trans*-splicing. The PTMs of  
15                   the invention comprise (i) one or more target binding domains that targets binding of the PTM to a skin cell specific target pre-mRNA and (ii) a 3' splice region that includes a branch point and a 3' splice acceptor site and/or 5' splice donor site. The 3' splice region may additionally contain a polypyrimidine tract. The PTMs may also contain (a) one or more spacer regions that separate the splice site from the target  
20                   binding domain, (b) mini-intron sequences, (c) ISAR (intronic splicing activator and repressor) consensus binding sites, and/or (d) ribozyme sequences. Additionally, the PTMs of the invention contain skin cell specific exon sequences designed to correct a skin cell specific genetic defect.

                  The present invention further provides methods and compositions for  
25                   real time imaging of gene expression in cells of the skin. The compositions of the invention include pre-*trans*-splicing molecules designed to interact with a target precursor messenger RNA molecule expressed within a cell of the skin and mediate a *trans*-splicing reaction resulting in the generation of a novel chimeric RNA molecule designed to encode a reporter molecule. The PTMs of the invention are engineered to  
30                   interact with target pre-mRNAs where the expression of the target pre-mRNA is correlated with a disease of the skin. Thus, the present invention provides methods

and compositions for the diagnosis and/or prognosis of skin disease in a subject. Such skin diseases include, but are not limited to disorders resulting from aberrant gene expression, proliferative disorders such as cancers or psoriasis, or infectious diseases.

A variety of different PTM molecules may be synthesized for use in the  
5 production of a novel chimeric RNA which complements a defective or inactive skin cell specific protein. The general design, construction and genetic engineering of such PTMs and demonstration of their ability to mediate successful *trans*-splicing reactions within the cell are described in detail in U.S. Patent Nos. 6,083,702, 6,013,487 and 6,280,978 as well as patent Serial Nos. 09/941,492, 09/756,095, 09/756,096 and  
10 09/756,097 the disclosures of which are incorporated by reference in their entirety herein.

As used herein, skin cell is defined as any of the different cell types found within the epidermal, dermal and/or first layer of the skin. Such skin cell types include, for example, melanocytes, keratinocytes, fibroblasts, blood vessel cells, hair  
15 follicle cells, neuronal cells of the skin and cancer cells of the skin.

The target binding domain of the PTM endows the PTM with a binding affinity. As used herein, a target binding domain is defined as any molecule, *i.e.*, nucleotide, protein, chemical compound, etc., that confers specificity of binding and anchors the skin cell specific pre-mRNA target closely in space to the PTM so that the  
20 spliceosome processing machinery in the nucleus can *trans*-splice a portion of the PTM to a portion of the skin cell specific target pre-mRNA. The target binding domain of the PTM may contain multiple binding domains which are complementary to and in anti-sense orientation to the targeted region of the selected pre-mRNA. The target binding domains may comprise up to several thousand nucleotides. In preferred  
25 embodiments of the invention the binding domains may comprise at least 10 to 30 and up to several hundred or more nucleotides. The specificity of the PTM may be increased significantly by increasing the length of the target binding domain. For example, the target binding domain may comprise several hundred nucleotides or more. In addition, although the target binding domain may be "linear" it is understood  
30 that the RNA may fold to form secondary structures that may stabilize the complex thereby increasing the efficiency of splicing. A second target binding region may be

placed at the 3' end of the molecule and can be incorporated into the PTM of the invention. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the target pre-RNA, forming a stable duplex. The ability to hybridize will depend on both the degree of complementarity and the length of the nucleic acid (See, for example, Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex. One skilled in the art can ascertain a tolerable degree of mismatch, length or structure of the duplex by use of standard procedures to determine the stability of the hybridized complex.

Binding may also be achieved through other mechanisms, for example, through triple helix formation, aptamer interactions, RNA lassos (see PCT application : PCT/US98/17268) antibody interactions or protein/nucleic acid interactions such as those in which the PTM is engineered to recognize a specific RNA binding protein, *i.e.*, a protein bound to a specific target pre-mRNA. Alternatively, the PTMs of the invention may be designed to recognize secondary structures, such as for example, hairpin structures resulting from intramolecular base pairing between nucleotides within an RNA molecule.

In a specific embodiment of the invention, the target binding domain is complementary and in anti-sense orientation to sequences in close proximity to the region of the keratinocyte specific target pre-mRNA targeted for *trans*-splicing. In a specific embodiment of the invention, the target binding domain is complementary and in antisense orientation to keratinocyte specific target pre-mRNAs nucleotide sequences, including but not limited to plectin, type VII collagen, type XVII collagen (Col17A1), and laminin. For a review of skin disorders and known genetic defects see Uitto *et al.*, (2000, *Human Gene Therapy* 11:2267-2275) the disclosure of which is incorporated by reference in its entirety herein.

The PTM molecule may also contains a 3' splice region that includes a branch point sequence and a 3' splice acceptor AG site and/or a 5' splice donor site.

The 3' splice region may further comprise a polypyrimidine tract. Consensus sequences for the 5' splice donor site and the 3' splice region used in RNA splicing are well known in the art (See, Moore, *et al.*, 1993, The RNA World, Cold Spring Harbor Laboratory Press, p. 303-358). In addition, modified consensus sequences that

5 maintain the ability to function as 5' donor splice sites and 3' splice regions may be used in the practice of the invention. Briefly, the 5' splice site consensus sequence is AG/GURAGU (where A=adenosine, U=uracil, G=guanine, C=cytosine, R=purine and /=the splice site). The 3' splice site consists of three separate sequence elements: the branch point or branch site, a polypyrimidine tract and the 3' consensus sequence

10 (YAG). The branch point consensus sequence in mammals is YNYURAC (Y=pyrimidine; N=any nucleotide). The underlined A is the site of branch formation. A polypyrimidine tract is located between the branch point and the splice site acceptor and is important for efficient branch point utilization and 3' splice site recognition. Other pre-messenger RNA introns beginning with the dinucleotide AU and ending

15 with the dinucleotide AC have been identified and referred to as U12 introns. U12 intron sequences as well as any sequences that function as splice acceptor/donor sequences may also be used to generate the PTMs of the invention.

A spacer region to separate the RNA splice site from the target binding domain may also be included in the PTM. The spacer region may be designed to

20 include features such as stop codons which would block translation of an unspliced PTM and/or sequences that enhance *trans*-splicing to the target pre-mRNA.

In a preferred embodiment of the invention, a "safety" is also incorporated into the spacer, binding domain, or elsewhere in the PTM to prevent non-specific *trans*-splicing. This is a region of the PTM that covers elements of the 3'

25 and/or 5' splice site of the PTM by relatively weak complementarity, preventing non-specific *trans*-splicing. The PTM is designed in such a way that upon hybridization of the binding /targeting portion(s) of the PTM, the 3' and/or 5'splice site is uncovered and becomes fully active.

The "safety" consists of one or more complementary stretches of *cis*-

30 sequence (or could be a second, separate, strand of nucleic acid) which weakly binds to one or both sides of the PTM branch point, polypyrimidine tract, 3' splice site

and/or 5' splice site (splicing elements), or could bind to parts of the splicing elements themselves. This "safety" binding prevents the splicing elements from being active (*i.e.* block U2 snRNP or other splicing factors from attaching to the PTM splice site recognition elements). The binding of the "safety" may be disrupted by the binding of  
 5 the target binding region of the PTM to the target pre-mRNA, thus exposing and activating the PTM splicing elements (making them available to *trans*-splice into the target pre-mRNA).

The PTMs of the invention may also contain skin cell specific exon sequences, which when *trans*-spliced to the skin cell specific target pre-mRNA, will  
 10 result in the formation of a chimeric RNA capable of encoding a functional keratinocyte specific protein. The genomic structure of keratinocyte specific genes such as plectin (Liu CG *et al.*, 1996, *Proc. Natl. Acad Sci USA* 93:4278-83), Col17A1 (Gatalica B *et al.*, 1997 *Am J Hum Genet* 60:352-365), type VII collagen (Li, K *et al.*, 1993, *Genomics* 16:733-9), and laminin (Pulkkinen L *et al.*, 1995 *Genomics* 25:192-  
 15 8), to name a few, are known and incorporated herein in their entirety. The specific exon sequences to be included in the structure of the PTM will depend on the specific mutation targeted for correction. Such mutations in the Col17A1 gene include but are not limited to those presented in Table I.

Table I

Mutations leading to preterminal stop codons	
3781C→G/4150insG	(McGrath <i>et al.</i> , 1995 <i>Nature Genetics</i> 11:83-86);
4003delTC/4003delTC	(McGrath <i>et al.</i> , 1996 <i>J. Invest Dermatol</i> 106:771-774);
3514ins25/G627V	(McGrath <i>et al.</i> , 1996 <i>Am J. Pathol</i> 148:1787-96);
4003delTC/Q1403X	(Darling <i>et al.</i> , 1997 <i>J. Invest. Dermatol</i> 108:463-8);
4003delTC/G803X	(Darling <i>et al.</i> , 1997 <i>J. Invest. Dermatol</i> 108:463-8);
2944del5/2944del5	(Gatalica <i>et al.</i> , 1997 <i>Am. J. Hum Genet</i> 60:352-65);
2944del5/Q1023X	(Gatalica <i>et al.</i> , 1997 <i>Am. J. Hum Genet</i> 60:352-65);
1706delA/R1226X	(Jonkman <i>et al.</i> , 1997 <i>Cell</i> 88:543-51);
2342delG/2342delG	(Scheffer <i>et al.</i> , 1997, <i>Hum Genet</i> 100:230-5);
Q1016X/Q1016X	(Schumann <i>et al.</i> , 1997, <i>Am J Hum Genet</i> 60:1344-53);
R1226X/R1226X	(Schumann <i>et al.</i> , 1997, <i>Am J Hum Genet</i> 60:1344-53);
520delAG/520delAG	(Floeth <i>et al.</i> , 1998, <i>J. Invest Dermatol</i> 111:528-33);
2965delG/2965delG	(Floeth <i>et al.</i> , 1998, <i>J. Invest Dermatol</i> 111:528-33);



<b>Mutations leading to preterminal stop codons</b>	
G539E/2666delTT	(Floeth <i>et al.</i> , 1998, <i>J. Invest Dermatol</i> 111:528-33);
G258X/G258X	(Shimizu <i>et al.</i> , 1998, <i>J. Invest Dermatol</i> 111:887-92);
4003delTC/4003delTC partially 4080insGG	(Darling <i>et al.</i> , 1999, <i>J. Clin Invest</i> 103:1371-7);
3781C→T (R1226X)/Ile-18del389	(Huber <i>et al.</i> , 2002, <i>J. Invest Dermatol</i> 118:185-92);
R795X/R795X	(Ruzzi <i>et al.</i> , 2001 <i>J. Invest Dermatol</i> 116:182-7)
<b>Acceptor splice-site mutations</b>	
2441-2A→G	(Chavanas <i>et al.</i> , 1997 <i>J. Invest Dermatol</i> 109:74-8);
2441-1 G→T/?	(Darling <i>et al.</i> , 1998 <i>J. Invest Dermatol</i> 110:165-9
3053-1 G→C/3871+1 G→C	(Pulkkinen <i>et al.</i> , 1999 <i>J. Invest Dermatol</i> 113:1114-8)
<b>Donor splice-site mutation</b>	
3053-1 G→C/3871+1 G→C	(Pulkkinen <i>et al.</i> , 1999 <i>J. Invest Dermatol</i> 113:1114-8)
4261+1 G→C/4261+1 G→C	(van Leusden <i>et al.</i> , 2001 81:887-94);
<b>Missense mutations</b>	
R1303Q/R1303Q	(Schumann <i>et al.</i> 1997 60:1344-53);
G633D/R145X	(Tasanen <i>et al.</i> , 2000 <i>J. Invest Dermatol</i> 115:207-12); and
<b>Digenic mutations</b>	
L855X/R1226X plus R635X (LAMB3 gene)	(Floeth <i>et al.</i> , 1999 <i>Am J. Hum Genet</i> 65:1530-7).

The PTM's of the invention may be engineered to contain a single skin cell specific exon sequence, multiple skin cell specific exon sequences, or alternatively a complete set of skin cell specific exon sequences. The number and identity of the skin cell specific sequences to be used in the PTMs will depend on the targeted specific mutation, and the type of *trans*-splicing reaction, *i.e.*, 5' exon replacement, 3' exon replacement or internal exon replacement that will occur (see Figure 1). In addition, to limit the size of the PTM, the molecule may include deletions in non-essential regions of skin cell specific target gene. The PTMs may also encode genes useful as markers or imaging reagents, therapeutic genes (toxins, prodrug activating enzymes) etc.

The present invention further provides PTM molecules wherein the coding region of the PTM is engineered to contain mini-introns. The insertion of mini-introns into the coding sequence of the PTM is designed to increase definition of

the exon and enhance recognition of the PTM donor site. Mini-intron sequences to be inserted into the coding regions of the PTM include small naturally occurring introns or, alternatively, any intron sequences, including synthetic mini-introns, which include 5' consensus donor sites and 3' consensus sequences which include a branch point, a 3' splice site and in some instances a polypyrimidine tract.

The mini-introns sequences are preferably between about 60-100 nucleotides in length, however, mini-intron sequences of increased lengths may also be used. In a preferred embodiment of the invention, the mini-intron comprises the 5' and 3' end of an endogenous intron. In a preferred embodiments of the invention, the 5' intron fragment is about 20 nucleotides in length and the 3' end is about 40 nucleotides in length.

In a specific embodiment of the invention, an intron of 528 nucleotides comprising the following sequences may be utilized. Sequence of the intron construct is as follows:

5' fragment sequence:

gtagttctttgttcttcactattaagaacttaatttggtgccatgtctcttttttctagttgtagtgctgga  
aggtattttggagaaattctacatgagcattaggagaatgtatgggtgtagtgcttgataatagaattgtccactgataatt  
tactctagtttttatttctcatatttttcagtggttttctccacatcttatatttgcaccacattcaacactgtagcgccgc

20

3' fragment sequence:

caactatctgaatcatgtgcccttctctgtgaacctctatcataataactgtcacactgtattgtaattgtct  
cttttactttccctgtatctttgtgcatagcagagtacctgaacaggaagtattttaaatatttgaatcaaatgagttaatagaa  
tctttacaataagaatatacattctgcttaggatgataattggaggcaagtgaatcctgagcgtgattgataatgacctaata  
atgatgggtttatttccag

25

In yet another specific embodiment of the invention, consensus ISAR sequences are included in the PTMs of the invention (Jones *et al.*, 2001 *Nucleic Acid Research* 29:3557-3565). Proteins bind to the ISAR splicing activator and repressor consensus sequence which includes a uridine-rich region that is required for 5' splice

30

site recognition by U1 SnRNP. The 18 nucleotide ISAR consensus sequence comprises the following sequence: GGGCUGAUUUUUCCAUGU. When inserted into the PTMs of the invention, the ISAR consensus sequences are inserted into the structure of the PTM in close proximity to the 5' donor site of intron sequences. In an embodiment of the invention, the ISAR sequences are inserted within 100 nucleotides from the 5' donor site. In a preferred embodiment of the invention the ISAR sequences are inserted within 50 nucleotides from the 5' donor site. In a more preferred embodiment of the invention the ISAR sequences are inserted within 20 nucleotides of the 5' donor site.

10               The compositions of the invention further comprise PTMs that have been engineered to include *cis*-acting ribozyme sequences. The inclusion of such sequences is designed to precisely define the length of the PTM by removing any additional or run off PTM transcription. The ribozyme sequences that may be inserted into the PTMs include any sequences that are capable of mediating a *cis*-acting (self-cleaving) RNA splicing reaction. Such ribozymes include but are not limited to 15 Group I and Group II ribozymes including but not limited to hammerhead, hairpin and hepatitis delta virus ribozymes (see, Chow *et al.*, 1994, *J Biol Chem* 269:25856-64).

In an embodiment of the invention, splicing enhancers such as, for example, sequences referred to as exonic splicing enhancers may also be included in 20 the structure of the PTMs. Transacting splicing factors, namely the serine/arginine-rich (SR) proteins, have been shown to interact with such exonic splicing enhancers and modulate splicing (See, Tacke *et al.*, 1999, *Curr. Opin. Cell Biol.* 11:358-362; Tian *et al.*, 2001, *J. Biological Chemistry* 276:33833-33839; Fu, 1995, *RNA* 1:663-680). Nuclear localization signals may also be included in the PTM molecule 25 (Dingwell and Laskey, 1986, *Ann .Rev. Cell Biol.* 2:367-390; Dingwell and Laskey, 1991, *Trends in Biochem. Sci.* 16:478-481). Such nuclear localization signals can be used to enhance the transport of synthetic PTMs into the nucleus where *trans*-splicing occurs. In addition, out of reading frame AUG start codons, Kozak sequences or other translational start sites may be included to prevent or minimize PTM self expression.

30               Additional features can be added to the PTM molecule either after, or before, the nucleotide sequence encoding a translatable protein, such as

polyadenylation signals or 5' splice sequences to enhance splicing, additional binding regions, "safety"-self complementary regions, additional splice sites, or protective groups to modulate the stability of the molecule and prevent degradation.

PTMs may also be generated that require a double-*trans*-splicing reaction for generation of a chimeric *trans*-spliced product. Such PTMs could be used to replace an internal exon which could be used for skin cell specific gene repair. PTMs designed to promote two *trans*-splicing reactions are engineered as described above, however, they contain both 5' donor sites and 3' splice acceptor sites. In addition, the PTMs may comprise two or more binding domains and splicer regions.

10 The splicer regions may be placed between the multiple binding domains and two splice sites or alternatively between the multiple binding domains.

A novel lacZ based assay has been developed for identifying optimal PTM sequences for mediating a desired *trans*-splicing reaction. The assay permits very rapid and easy testing of many PTMs for their ability to *trans*-splice. A LacZ

15 keratinocyte specific chimeric target is presented in Figure 2A. This target consists of the coding region for LacZ (minus 120 nucleotide from the central coding region), split into a 5' "exon" and a 3' "exon". Separating these exons is a genomic fragment of the human Col17A1 gene including intron 51. All donor and acceptor sites in this target are functional but a *cis*-spliced target, which generates a LacZ-keratinocyte

20 specific chimeric mRNA, is non-functional. *Trans*-splicing between the PTM and target will generate a full length functional LacZ mRNA.

Each new PTM to be tested is transiently co-transfected with the LacZ-keratinocyte specific target using Lipofectamine reagents and then assayed for  $\beta$ -galactosidase activity after 48 hours. Total RNA samples may also be prepared and

25 assessed by RT-PCR using target and PTM specific primers for the presence of correctly spliced repaired products and the level of repaired product. Each *trans*-splicing domain is engineered with several unique restriction sites, so that when an efficiently spliced sequence is identified based on the analysis of  $\beta$ -gal activity and RT-PCR data, part of or the complete *trans*-splicing domain, can be readily sub-

30 cloned into a skin cell specific PTM.

When specific PTMs are to be synthesized *in vitro* (synthetic PTMs), such PTMs can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization to the target specific mRNA, transport into the cell, etc. For example, modification of a PTM to reduce the overall charge can enhance the cellular uptake of the molecule. In addition modifications can be made to reduce susceptibility to nuclease or chemical degradation. The nucleic acid molecules may be synthesized in such a way as to be conjugated to another molecule such as a peptides (*e.g.*, for targeting host cell receptors *in vivo*), or an agent facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents (see, *e.g.*, Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the nucleic acid molecules may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Various other well-known modifications to the nucleic acid molecules can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of deoxyribonucleotides, peptide nucleic acids and ribonucleotides to the 5' and/or 3' ends of the molecule. In some circumstances where increased stability is desired, nucleic acids having modified internucleoside linkages such as 2'-O-methylation may be preferred. Nucleic acids containing modified internucleoside linkages may be synthesized using reagents and methods that are well known in the art (see, Uhlmann *et al.*, 1990, *Chem. Rev.* 90:543-584; Schneider *et al.*, 1990, *Tetrahedron Lett.* 31:335 and references cited therein).

The synthetic PTMs of the present invention are preferably modified in such a way as to increase their stability in the cells. Since RNA molecules are sensitive to cleavage by cellular ribonucleases, it may be preferable to use as the competitive inhibitor a chemically modified oligonucleotide (or combination of

oligonucleotides) that mimics the action of the RNA binding sequence but is less sensitive to nuclease cleavage. In addition, the synthetic PTMs can be produced as nuclease resistant circular molecules with enhanced stability to prevent degradation by nucleases (Puttaraju *et al.*, 1995, *Nucleic Acids Symposium Series No.* 33:49-51;

- 5 Puttaraju *et al.*, 1993, *Nucleic Acid Research* 21:4253-4258). Other modifications may also be required, for example to enhance binding, to enhance cellular uptake, to improve pharmacology or pharmacokinetics or to improve other pharmaceutically desirable characteristics.

- Modifications, which may be made to the structure of the synthetic
- 10 PTMs include but are not limited to backbone modifications such as use of:
- (i) phosphorothioates (X or Y or W or Z=S or any combination of two or more with the remainder as O). *e.g.*, Y=S (Stein, C. A., *et al.*, 1988, *Nucleic Acids Res.*, 16:3209-3221), X=S (Cosstick, R., *et al.*, 1989, *Tetrahedron Letters*, 30, 4693-4696), Y and Z=S (Brill, W. K.-D., *et al.*, 1989, *J. Amer. Chem. Soc.*, 111:2321-
  - 15 2322); (ii) methylphosphonates (*e.g.*, Z=methyl (Miller, P. S., *et al.*, 1980, *J. Biol. Chem.*, 255:9659-9665); (iii) phosphoramidates (Z=N-(alkyl)<sub>2</sub> *e.g.*, alkyl methyl, ethyl, butyl) (Z=morpholine or piperazine) (Agrawal, S., *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:7079-7083) (X or W=NH) (Mag, M., *et al.*, 1988, *Nucleic Acids Res.*, 16:3525-3543); (iv) phosphotriesters (Z=O-alkyl *e.g.*, methyl, ethyl, *etc*) (Miller,
  - 20 P. S., *et al.*, 1982, *Biochemistry*, 21:5468-5474); and (v) phosphorus-free linkages (*e.g.*, carbamate, acetamidate, acetate) (Gait, M. J., *et al.*, 1974, *J. Chem. Soc. Perkin I*, 1684-1686; Gait, M. J., *et al.*, 1979, *J. Chem. Soc. Perkin I*, 1389-1394).

- In addition, sugar modifications may be incorporated into the PTMs of the invention. Such modifications include the use of: (i) 2'-ribonucleosides (R=H);
- 25 (ii) 2'-O-methylated nucleosides (R=OMe) (Sproat, B. S., *et al.*, 1989, *Nucleic Acids Res.*, 17:3373-3386); and (iii) 2'-fluoro-2'-riboxynucleosides (R=F) (Krug, A., *et al.*, 1989, *Nucleosides and Nucleotides*, 8:1473-1483).

- Further, base modifications that may be made to the PTMs, including but not limited to use of: (i) pyrimidine derivatives substituted in the 5-position (*e.g.*,
- 30 methyl, bromo, fluoro *etc*) or replacing a carbonyl group by an amino group (Piccirilli, J. A., *et al.*, 1990, *Nature*, 343:33-37); (ii) purine derivatives lacking specific nitrogen

atoms (e.g., 7-deaza adenine, hypoxanthine) or functionalized in the 8-position (e.g., 8-azido adenine, 8-bromo adenine) (for a review see Jones, A. S., 1979, *Int. J. Biolog. Macromolecules*, 1:194-207).

In addition, the PTMs may be covalently linked to reactive functional groups, such as: (i) psoralens (Miller, P. S., *et al.*, 1988, *Nucleic Acids Res.*, Special Pub. No. 20, 113-114), phenanthrolines (Sun, J-S., *et al.*, 1988, *Biochemistry*, 27:6039-6045), mustards (Vlassov, V. V., *et al.*, 1988, *Gene*, 72:313-322) (irreversible cross-linking agents with or without the need for co-reagents); (ii) acridine (intercalating agents) (Helene, C., *et al.*, 1985, *Biochimie*, 67:777-783); (iii) thiol derivatives ( reversible disulphide formation with proteins) (Connolly, B. A., and Newman, P. C., 1989, *Nucleic Acids Res.*, 17:4957-4974); (iv) aldehydes (Schiff's base formation); (v) azido, bromo groups (UV cross-linking); or (vi) ellipticines (photolytic cross-linking) (Perrouault, L., *et al.*, 1990, *Nature*, 344:358-360).

In an embodiment of the invention, oligonucleotide mimetics in which the sugar and internucleoside linkage, *i.e.*, the backbone of the nucleotide units, are replaced with novel groups can be used. For example, one such oligonucleotide mimetic which has been shown to bind with a higher affinity to DNA and RNA than natural oligonucleotides is referred to as a peptide nucleic acid (PNA) (for review see, Uhlmann, E. 1998, *Biol. Chem.* 379:1045-52). Thus, PNA may be incorporated into synthetic PTMs to increase their stability and/or binding affinity for the target pre-mRNA.

In another embodiment of the invention synthetic PTMs may covalently linked to lipophilic groups or other reagents capable of improving uptake by cells. For example, the PTM molecules may be covalently linked to: (i) cholesterol (Letsinger, R. L., *et al.*, 1989, *Proc. Natl. Acad. Sci. USA*, 86:6553-6556); (ii) polyamines (Lemaitre, M., *et al.*, 1987, *Proc. Natl. Acad. Sci. USA*, 84:648-652); other soluble polymers (e.g., polyethylene glycol) to improve the efficiency with which the PTMs are delivered to a cell. In addition, combinations of the above identified modifications may be utilized to increase the stability and delivery of PTMs into the target cell.

The PTMs of the invention can be used in methods designed to produce a novel chimeric RNA in a target cell so as to result in correction of skin cell specific genetic defects. The methods of the present invention comprise delivering to a skin cell a PTM which may be in any form used by one skilled in the art, for  
5 example, an RNA molecule, or a DNA vector which is transcribed into a RNA molecule, wherein said PTM binds to a skin cell specific pre-mRNA and mediates a *trans*-splicing reaction resulting in formation of a chimeric RNA comprising a portion of the PTM molecule spliced to a portion of the pre-mRNA.

10                   5.2 SYNTHESIS OF THE *TRANS*-SPLICING MOLECULES

The nucleic acid molecules of the invention can be RNA or DNA or derivatives or modified versions thereof, single-stranded or double-stranded. By nucleic acid is meant a PTM molecule or a nucleic acid molecule encoding a PTM molecule, whether composed of deoxyribonucleotides or ribonucleosides, and whether  
15 composed of phosphodiester linkages or modified linkages. The term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil). In addition, the PTMs of the invention may comprise, DNA/RNA, RNA/protein or DNA/RNA/protein chimeric molecules that are designed to enhance the stability of  
20 the PTMs.

The PTMs of the invention can be prepared by any method known in the art for the synthesis of nucleic acid molecules. For example, the nucleic acids may be chemically synthesized using commercially available reagents and synthesizers by methods that are well known in the art (see, *e.g.*, Gait, 1985, *Oligonucleotide*  
25 *Synthesis: A Practical Approach*, IRL Press, Oxford, England).

Alternatively, synthetic PTMs can be generated by *in vitro* transcription of DNA sequences encoding the PTM of interest. Such DNA sequences can be incorporated into a wide variety of vectors downstream from suitable RNA polymerase promoters such as the T7, SP6, or T3 polymerase promoters. Consensus  
30 RNA polymerase promoter sequences include the following:



T7: TAATACGACTCACTATAGGGGAGA

SP6: ATTTAGGTGACACTATAGAAGNG

T3: AATTAACCCTCACTAAAGGGAGA.

5 The base in bold is the first base incorporated into RNA during transcription. The underline indicates the minimum sequence required for efficient transcription.

10 RNAs may be produced in high yield via *in vitro* transcription using plasmids such as SPS65 and Bluescript (Promega Corporation, Madison, WI). In addition, RNA amplification methods such as Q- $\beta$  amplification can be utilized to produce the PTM of interest.

15 The PTMs may be purified by any suitable means, as are well known in the art. For example, the PTMs can be purified by gel filtration, affinity or antibody interactions, reverse phase chromatography or gel electrophoresis. Of course, the skilled artisan will recognize that the method of purification will depend in part on the size, charge and shape of the nucleic acid to be purified.

20 The PTM's of the invention, whether synthesized chemically, *in vitro*, or *in vivo*, can be synthesized in the presence of modified or substituted nucleotides to increase stability, uptake or binding of the PTM to a target pre-mRNA. In addition, following synthesis of the PTM, the PTMs may be modified with peptides, chemical agents, antibodies, or nucleic acid molecules, for example, to enhance the physical properties of the PTM molecules. Such modifications are well known to those of skill in the art.

25 In instances where a nucleic acid molecule encoding a PTM is utilized, cloning techniques known in the art may be used for cloning of the nucleic acid molecule into an expression vector. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et al.* (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY.

The DNA encoding the PTM of interest may be recombinantly engineered into a variety of host vector systems that also provide for replication of the DNA in large scale and contain the necessary elements for directing the transcription of the PTM. The use of such a construct to transfect target cells in the patient will  
5 result in the transcription of sufficient amounts of PTMs that will form complementary base pairs with the endogenously expressed cell specific pre-mRNA targets and thereby facilitate a *trans*-splicing reaction between the complexed nucleic acid molecules. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of the PTM molecule. Such a vector can  
10 remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired RNA, *i.e.*, PTM. Such vectors can be constructed by recombinant DNA technology methods standard in the art.

Vectors encoding the PTM of interest can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression  
15 of the sequence encoding the PTM can be regulated by any promoter/enhancer sequences known in the art to act in mammalian, preferably human cells. Such promoters/enhancers can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Benoist, C. and Chambon, P. 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous  
20 sarcoma virus (Yamamoto *et al.*, 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, 1982, *Nature* 296:39-42), the viral CMV promoter, the human  $\beta$ -chorionic gonadotropin-6 promoter (Hollenberg *et al.*, 1994, *Mol. Cell. Endocrinology* 106:111-119), etc. In a preferred  
25 embodiment of the invention, keratinocyte specific promoter/enhancer sequences may be used to promote the synthesis of PTMs in keratinocytes. Such promoters include, for example, the keratin 14 promoter which targets gene expression to the basal layer of the epidermis (Wang X *et al.*, 1997, *Proc Natl. Acad Sci* 94:219-26), the loricrin promoter (Disepio *et al.*, 1995, *J. Biol Chem* 270:10792-9) which targets expression  
30 to the upper layers of the epidermis and the involucrin promoter transcriptional response element (Phillips *et al.*, 2000, *Biochem. J.* 348:45-53).

Vectors for use in the practice of the invention include any eukaryotic expression vectors, including but not limited to viral expression vectors such as those derived from the class of retroviruses, adenoviruses or adeno-associated viruses.

5        5.3 USES AND ADMINISTRATION OF TRANS-SPLICING MOLECULES

The compositions and methods of the present invention can be utilized to correct skin cell specific genetic defects. Specifically, targeted *trans*-splicing, including double-*trans*-splicing reactions, 3' exon replacement and/or 5' exon replacement can be used to repair or correct skin cell specific transcripts that are either truncated or contain mutations. The PTMs of the invention are designed to interact with spliceosomes to cleave a targeted transcript upstream or downstream of a specific mutation or upstream of a premature 3' stop termination and correct the mutant transcript via a *trans*-splicing reaction which replaces the portion of the transcript containing the mutation with a functional sequence. PTMs may also be utilized to rewrite the coding sequence of virtually any gene which undergoes spliceosome processing, to insert any desired gene sequence into the target mRNA.

Various delivery systems are known and can be used to transfer the compositions of the invention into cells, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the composition, receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral, adenoviral, adeno-associated viral or other vector, injection of DNA, electroporation, calcium phosphate mediated transfection, etc.

The compositions and methods can be used to provide sequences encoding a functional biologically active skin cell specific molecule to cells of an individual with an inherited genetic disorder or other type of skin disorder where expression of the missing or mutant gene product produces a normal phenotype. In addition, the compositions and methods of the invention can be used to inhibit the proliferation of cells of the skin in an individual with cancer of the skin or psoriasis, for example. In such instances the PTMs may be designed to interact with target pre-

mRNAs that encode regulators of skin cell proliferation and inhibit the expression of such regulators. and encodes a reporter molecule.

In a preferred embodiment, nucleic acids comprising a sequence encoding a PTM are administered to promote PTM function, by way of gene delivery and expression into a host cell. In this embodiment of the invention, the nucleic acid mediates an effect by promoting PTM production. Any of the methods for gene delivery into a host cell available in the art can be used according to the present invention. For general reviews of the methods of gene delivery see Strauss, M. and Barranger, J.A., 1997, *Concepts in Gene Therapy*, by Walter de Gruyter & Co., Berlin; Goldspiel *et al.*, 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 33:573-596; Mulligan, 1993, *Science* 260:926-932; and Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; 1993, *TIBTECH* 11(5):155-215. Exemplary methods are described below.

Delivery of the PTM into a host cell may be either direct, in which case the host is directly exposed to the PTM or PTM encoding nucleic acid molecule, or indirect, in which case, host cells are first transformed with the PTM or PTM encoding nucleic acid molecule *in vitro*, then transplanted into the host. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene delivery.

In a specific embodiment, the nucleic acid is directly administered *in vivo*, where it is expressed to produce the PTM. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by infection using a defective or attenuated retroviral or other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see *e.g.*, Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432).

In a specific embodiment, a viral vector that contains the PTM can be used. For example, a retroviral vector can be utilized that has been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA (see Miller *et al.*, 1993, *Meth. Enzymol.* 217:581-599).

5 Alternatively, adenoviral or adeno-associated viral vectors can be used for gene delivery to cells or tissues. (See, Kozarsky and Wilson, 1993, *Current Opinion in Genetics and Development* 3:499-503 for a review of adenovirus-based gene delivery).

In a preferred embodiment of the invention an adeno-associated viral  
10 vector may be used to deliver nucleic acid molecules capable of encoding the PTM. The vector is designed so that, depending on the level of expression desired, the promoter and/or enhancer element of choice may be inserted into the vector.

Another approach to gene delivery into a cell involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium  
15 phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. The resulting recombinant cells can be delivered to a host by various methods known in the art. In a preferred embodiment, the cell used for gene delivery  
20 is autologous to the host cell.

In a specific embodiment of the invention, skin cells, such as keratinocytes, may be removed from a subject having a skin disorder and transfected with a nucleic acid molecule capable of encoding a PTM designed to correct a skin cell specific disorder such as a genetic disorder. Cells may be further selected, using  
25 routine methods known to those of skill in the art, for integration of the nucleic acid molecule into the genome thereby providing a stable cell line expressing the PTM of interest. Such cells are then transplanted into the subject thereby providing a source of skin cell specific protein.

The present invention also provides for pharmaceutical compositions  
30 comprising an effective amount of a PTM or a nucleic acid encoding a PTM, and a pharmaceutically acceptable carrier. In a specific embodiment, the term

"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical sciences" by E.W. Martin.

In specific embodiments, pharmaceutical compositions are administered in diseases or disorders involving an absence or decreased (relative to normal or desired) level of an endogenous skin cell specific protein or function, for example, in hosts where the skin cell specific protein is lacking, genetically defective, biologically inactive or underactive, or under expressed. Such disorders include but are not limited to epidermal fragility disorders, keratinization disorders, hair disorders, pigmentation disorders, prophyrias, pre-cancerous and cancer disorders. In addition, pharmaceutical compositions may be administered in proliferative disorders of the skin, such as cancers and psoriasis, where the goal is to inhibit the proliferation of such cells. The activity of the skin cell specific protein encoded for by the chimeric mRNA resulting from the PTM mediated *trans*-splicing reaction can be readily detected, *e.g.*, by obtaining a host tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for mRNA or protein levels, structure and/or activity of the expressed chimeric mRNA. Many methods standard in the art can be thus employed, including but not limited to immunoassays to detect and/or visualize the protein encoded for by the chimeric mRNA (*e.g.*, Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect formation of chimeric mRNA expression by detecting and/or visualizing the presence of chimeric mRNA (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and reverse-transcription PCR, etc.), etc.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment, *i.e.*, skin. This may be achieved by, for example, and not by way of limitation, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, or by means of an implant, said implant being of a porous, non-porous, or gelatinous

material, including membranes, such as sialastic membranes, or fibers. Other control release drug delivery systems, such as nanoparticles, matrices such as controlled-release polymers, hydrogels.

The PTM will be administered in amounts which are effective to  
5 produce the desired effect in the targeted cell. Effective dosages of the PTMs can be determined through procedures well known to those in the art which address such parameters as biological half-life, bioavailability and toxicity. The amount of the composition of the invention which will be effective will depend on the severity of the skin disorder being treated, and can be determined by standard clinical techniques.  
10 Such techniques include analysis of skin samples to determine levels of protein expression. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges.

The present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the  
15 pharmaceutical compositions of the invention optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

20

#### 6. EXAMPLE: TRANS-SPLICING OF THE COL17A1 GENE

The data presented below demonstrates the feasibility of using *trans*-splicing reactions in a keratinocyte specific context for skin gene therapy. In particular, the data indicates that (i) the *trans*-splicing reaction is accurate between the  
25 target and PTM in keratinocytes; (ii) effectivity can be modulated by incorporating stem-loop structures in the *trans*-splicing domain; and (iii) intron 51 of the Col17A1 gene can be targeted and *trans*-spliced using spliceosomal mediated *trans*-splicing at the pre-mRNA level in keratinocytes.

## 6.1 MATERIALS AND METHODS

Cell culture. Human embryonic kidney cells (293T) were grown at 37°C and 5% CO<sub>2</sub> in a humidified incubator in DMEM medium supplemented with 10% FBS (Life Technologies, Gaithersburg, MD). Passaging of the cells was performed every 3-4 days using 1% Trypsin-EDTA (PAA Laboratories, Linz, Austria) and cells were replated at the desired density. Human keratinocytes used in all experiments were prepared from neonatal foreskins using a standard protocol. Cells were counted and plated on 60 mm plates at the desired density and grown for 10-12 days at 37°C and 5% CO<sub>2</sub> in a humidified incubator in KGM-2 medium (Clonetics/Bio-Whittaker, Walkersville, MD) to a confluency of approximately 50-60%. Medium was changed every 2-3 days.

Primary keratinocytes from a GABEB patient homozygous for 4003delTC in COL17A1 were immortalized with a human papilloma virus HPV16 E6 and E7 vector and continuously passaged; the resulting cell line did not express collagen XVII protein. Cells were maintained at 37°C and 5% CO<sub>2</sub> in KGM-2 medium (Clonetics) and passaged every 5-7 days at a confluency of approximately 70% and replated at the desired density. Medium was changed every 2-3 days.

Target construction. LacZ-T1 (Figure 2A) included a lacZ 5' "exon" (1-1788 bp) followed by intron 51 of the Collagen 17A1 gene (282 bp) and a LacZ 3' "exon" (1789-3174 bp). This lacZ 3' exon contained two stop codons at position 1800 bp. Intron 51 of Col17A1 was amplified by PCR with Pfu DNA polymerase (Stratagene, La Jolla, CA) using genomic DNA as template and primers:

Int51U (5'-CGGGATCCGTAGGTGCCCCGACGGTGATG-3'); and  
Int51D (5'-CTAGGGTAACCAGGGTGAGAAGCTGCATGAGT-3').

The amplified product was digested with BamHI and BstEII (New England Biolabs, Beverly, MA) and inserted between the two lacZ exons. T2 (Figure 2B) included the genomic sequence of exon 51, intron 51 and exon 52 followed by a FLAG sequence. The genomic sequence of exon 51, intron 51 and exon 52 was amplified using Pfu DNA polymerase and primers:



COLI-F (5'-CTAGGCTAGCCTGCCGGCTTGTCATTCATCC-3') and  
COLI-R (5'-CTAGAAGCTTTTACTTGTTCATCGTCGTCCTTGTA  
GTCGCTGCATGCTCTCTGACACC-3').

The FLAG sequence was introduced by primer COLI-R. The PCR  
5 product was digested with NheI and HindIII (New England Biolabs, Beverly, MA) and  
inserted in pcDNA3.1 (Invitrogen, Carlsbad, CA).

Pre-trans-splicing molecules (PTMs). pCOL17-PTM1 (Figure 2C)  
was constructed by digesting PTM14 (Intronn Inc., Rockville, MD) with EcoRI and  
KpnI replacing the CFTR binding domain (Mansfield SG *et al.*, 2000 7:1885-95) with  
10 a 80 bp oligonucleotide containing a 32 bp antisense binding domain (BD), a 18 bp  
spacer, branch point (BP), a polypyrimidine tract (PPT), and an acceptor AG  
dinucleotide followed by a lacZ 3' exon (1789-3174 bp). The use of BP and PPT  
follows consensus sequences which are needed for performance of the two phosphoryl  
transfer reactions involved in *cis*-splicing and also in *trans*-splicing, pCOL17-PTM4  
15 and pCOL17-PTM6 were constructed by digesting PTM1, 3, and 5 with KpnI and  
HindIII and replacing the lacZ 3' exon with the exon 52 to 56 cDNA sequence of  
COLI7A1 (Figure 2D). The cDNA sequence was amplified with Pfu DNA  
polymerase from poly-dT primed cDNA using the following primers:

20 COL2-F (5'-CTAGGGTACCTCTTCTTTTTTTTGATATCCTGCA  
GGTCCTGATGTGCGCAGC-3'); and  
COL-2-R (5'-CTAGAAGCTTTTATGGAGACCTTGGACCTAAG-  
3').

The amplified product was digested with KpnI and HindIII and cloned  
25 into PTMs 1, 3, and 5. All constructs were sequenced to confirm their correct  
sequence.

Transfection into 293T cells. 293T cells were used for preliminary  
experiments due to their lack of endogenous COLI7AI mRNA. The day before  
transfection,  $1.15 \times 10^6$  cells were plated on 60 mm plates and grown for 24 hr. Cells  
30 were transfected with expression plasmids using LipofectaminePlus reagent (Life

Technologies) according to manufacturer's protocol. Cells were harvested 48 hr after transfection.

Transfection into primary keratinocytes (hKC). hKC were grown as described above for 10–12 days to a confluency of 50–60%. Cells were transfected using LipofectaminePlus reagent and KGM-2 without supplements. KGM-2 medium containing 2x supplements was added 3 hours after transfection. The medium was replaced by regular KGM-2 after 12 hr and incubated for additional 24–48 hr at 37°C.

Transfection into immortalized GABEB-keratinocytes. GABEB keratinocytes were plated on 60 mm diameter plates at a density of  $1 \times 10^6$  cells/ml and grown to 60–70% confluency. Cells were transfected with FuGENE 6 (Roche) transfection reagent (6  $\mu$ l/ $\mu$ g DNA) and DNA in supplement-free KGM-2 medium according to the manufacturer's protocol. The transfection reaction was added dropwise to the cells and incubated for 3 hr at 37°C in 5% CO<sub>2</sub>. Then KGM-2 with 2x supplements was added and the incubation was continued overnight. The next morning the medium was replaced with fresh medium and incubated for additional 24–48 hr.

Total RNA isolation. 48 hr after transfection the plates were rinsed with phosphate buffered saline (PBS) once and the cells were harvested in 1 ml PBS. The cells were pelleted and the supernatant was removed. Total RNA was isolated using MasterPure RNA/DNA purification kit (Epicentre Technologies, Madison, WI). Contaminating DNA was removed by DNase I treatment for 30–60 min at 37°C.

Reverse Transcription Polymerase Chain Reaction. RT-PCR was performed using a SuperScript OneStep<sup>TM</sup> RT-PCR Kit (Life Technologies) according to the manufacturer's protocol. Each reaction contained 50 to 500 ng of total RNA and 100 ng of a 5'- and 3'-specific primer in a 25  $\mu$ l reaction volume. RT-PCR products were separated by gel-electrophoresis using 2% agarose gels. Primers used to estimate the products of *cis* and *trans*-splicing were as follows:

LAC9F (5'-ATCAAATCTGTCGATCCTTCC-3'); and  
KI-3R (5'-GACTGATCCACCCAGTCCCATTA-3') for *cis*-, and  
LAC9F and

KI-5R (5'-GACTGATCCACCCAGTCCCAGAC-3') for *trans*-splicing. For position of these primers on the plasmids see Figure 2A. RT-PCR analysis for the COLI7A1-mini-gene *cis*-splicing was performed using the following primers:

5 Ex51-1F (5'-CATCCCAGGCCCTCCAGGAC-3'); and  
FLAG-R (5'-TTGTCATCGTCGTCCTTGTAG-3'), while Primers  
Ex51-1F and

KI-53-1R (5'-GTAGGCCATCCCTTGCA-3') were used for the  
detection of *trans*-splicing. For position of these primers on the plasmids see Figure  
10 5B.

Protein preparation and  $\beta$ -gal assay. The total protein from transfected cells was isolated by a freeze and thaw method and assayed for  $\beta$ -gal activity as described (Invitrogen). Total protein concentration was measured by the dye-binding assay according to Bradford using Bio-Rad protein assay reagent (BIO-RAD, Hercules, CA). All measurements of protein concentrations and  $\beta$ -gal activities were performed with a Pharmacia Ultrospec 2000 Spectrophotometer (Amersham Pharmacia, Uppsala, Sweden).

In situ staining for  $\beta$ -gal. The expression of functional  $\beta$ -gal was monitored using a  $\beta$ -gal staining kit (Invitrogen) following the manufacturer's protocol. The percentage of  $\beta$ -gal positive cells was determined by counting stained versus unstained cells in five randomly selected fields.

DNA sequencing. Constructs and RT-PCR products were sequenced using an ABI Prism automated sequencer (Applied Biosystems, Foster City, CA), Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems), and 2 pmol of primer per reaction to verify sequences.

RNA structure determination. RNA secondary structures for PTM binding domain design were predicted using the RNA folding program mfold by Zucker and Turner (<http://mfold2.wustl.edu/~mfold/ma/form1.cgi>).

Quantitative real-time RT-PCR analysis. Real-time RT-PCR was performed using a LightCycler (Roche Diagnostics, Mannheim, Germany). 1  $\mu$ g total

RNA obtained from the transfection experiments was oligo dT primed and reversed transcribed to cDNA using M-MLV-RT (Promega, Madison, WI). PCR reactions were performed according to the manufacturers protocol using 1 µl of the cDNA solution, 3 µl SYBR-green master mix (Roche), 2 pmol of primer Lac9F, 2 pmol of primer KI-3R for the *cis*-splicing, and 2 pmol of Primer KI-5R for the *trans*-splicing product.

## 6.2 RESULTS

The LacZ model repair-system. To evaluate the efficiency of *trans*-splicing in various cell types we used a lacZ model repair-system. It consists of a mutant β-gal target expressed from plasmid LacZ-T1, and a second plasmid expressing a pre-*trans*-splicing molecule (PTM) which were cotransfected into the respective cells. First, *cis*-splicing was examined by transfecting LacZ-T1 plasmid (Figure 2A) into 293T cells followed by preparation of total RNA and RT-PCR analysis. A 302 bp RT-PCR product was detected using primers Lac9F (lacZ 5'exon specific) and KI-3R (LacZ 3'Stop codon specific), demonstrating the expected size for accurate *cis*-splicing (Figure 3A; lanes 2; 6; 7; 8). The RT-PCR product was sequenced to confirm the accuracy of splice site usage (Figure 3B, upper panel). Because of the inclusion of in-frame stop codons there is no measurable β-gal activity exceeding basal expression of mock transfections (Figure 3C). 293T cells transfected with LacZ-T1 alone showed complete absence of positively stained cells in cell culture (Figure 4, top panel, control).

The second component of the lacZ model repair-system are the PTMs. PTM1 included a 32 bp antisense binding domain exactly complementary to the 3' end of COL17A1 intron 51, and 18 bp spacer sequence, yeast branch point (BP), polypyrimidine tract (PPT) and a 3' splice acceptor site followed by the coding sequence of the wild-type lacZ gene fragment from nucleotide 1789 to 3174 inserted into a pcDNA3.1 mammalian expression vector (Figure 2C). This construct was predicted to produce RNA which binds to and repairs the defective pre-mRNA transcribed from LacZ-T1 by replacing the mutation in the 3'exon of the target pre-mRNA and therefore restoring β-gal activity. As expected the PTM did not yield

functional mRNA (Figure 3A; lanes 3, 4, 5; left picture) and  $\beta$ -gal activity (Figure 3C) when transfected alone.

Testing for RNA repair and protein function restoration in an epithelia cell-line. The ability of PTM-induced RNA *trans*-splicing to repair the chosen pre-mRNA target was examined in a transient co-transfection assay. Plasmids expressing LacZ-T1 pre-mRNA and PTM1 pre-mRNA were co-transfected into 293T cells. The product of the *trans*-splicing reaction should be an mRNA consisting of the 5'exon of lacZ and the inserted normal 3'exon of lacZ, which should be translated into functional  $\beta$ -gal protein. Analysis of total RNA by RT-PCR using a target specific primer (Lac9F) and a lacZ-PTM specific primer (KI-5R) showed a RT-PCR product of the predicted length (298 bp) (Figure 3A; lanes 6, 7, 8; right picture). This product was not observed in cells transfected with either LacZ-T1 or PTM1 alone (Figure 3A; lanes 2, 3, 4, 5; right picture). Sequencing of the 298 bp *trans*-spliced RT-PCR product demonstrated that *trans*-splicing was accurate between LacZ-T1 pre-mRNA and PTM1 pre-mRNA (Figure 3B; lower panel). In addition, genomic DNA was prepared from co-transfected cells and analyzed by PCR using the target specific Lac9F as a forward and the PTM specific KI-5R as a reverse primer to rule out recombination events on the DNA level between PTM and target. No PCR fragment was detected indicating the absence of recombination events.

*Trans*-splicing between LacZ-T1 pre-mRNA and PTM1 pre-mRNA restores  $\beta$ -gal activity. The repair of defective lacZ pre-mRNA by *trans*-splicing and production of functional  $\beta$ -gal protein was investigated in 293T cells co-transfected with target and PTM plasmids. Staining of co-transfected 293T cells revealed  $\beta$ -gal positive cells (25% of total cells) (Figure 4 upper panel, right), indicating the production of corrected RNA. In contrast, cells transfected with either LacZ-T1 or PTM1 alone did not produce any functional  $\beta$ -gal as indicated by the complete absence of  $\beta$ -gal positive cells.

To further quantify the amount of  $\beta$ -gal activity produced by *trans*-splicing repair enzyme activity was measured in a colorimetric assay.  $\beta$ -gal activity in protein extracts prepared from cells transfected with either LacZ-T1 target or PTM1 alone was almost identical to the background levels. In contrast, cells co-transfected

with LacZ-T1 and PTM1 produced a significant amount of  $\beta$ -gal activity compared to background (~100 fold increase) (Figure 3C). These data demonstrate the efficient repair of defective LacZ-T1 pre-mRNA by trans-splicing restoring  $\beta$ -gal protein function.

5                    The length of the binding domains can modulate *trans*-splicing efficiency and specificity. To determine how the length of the binding domains influences the efficiency of *trans*-splicing between LacZ-T1 and PTMs, PTM3 and PTM5 were constructed (Figure 2C). PTM3 contains a shorter binding of 25 nt with distinct changes in the nucleotide sequence to achieve a tight RNA secondary  
10 structure that should reduce non-specific binding to other RNA targets. This change was made based on the predictions gained from the RNA program of Zucker and Turner <http://mfold2.wustl.edu/~mfold/ma/formI.cgi>). This PTM (PTM3) was co-transfected with LacZ-T1 and its repair efficiency was measured by RT-PCR,  $\beta$ -gal quantitative assay and in situ staining for  $\beta$ -gal. PTM3 showed a modest increase in  
15  $\beta$ -gal activity compared to PTM1 indicating more efficient binding and *trans*-splicing. A third PTM, PTM5 was constructed using a longer binding domain of 52 nt (Figure 2C). Transfections with this PTM showed a 3 fold increase in restoration of  $\beta$ -gal activity compared to PTM1 or PTM3, respectively (Figure 3C).

To quantify the *trans*-spliced mRNA compared to the *cis*-spliced  
20 product, semi-quantitative real time PCR was performed. As expected, control reactions did not show any *trans*-spliced product, co-transfection of LacZ-T1 and PTM1 yielded 1.9% of repaired lacZ mRNA compared to *cis*-spliced target. Co-transfection of LacZ-T1 and PTM3 improved *trans*-splicing to 2.1%. The extension of the binding domain length contained in PTM5 further increased the amount of  
25 repaired mRNA to 6.5% of *cis*-spliced target confirming the results obtained by the  $\beta$ -gal protein assay (Table II).

Table II  
Relative efficiency of *trans*-splicing in keratinocytes  
measured by semiquantitative real-time PCR<sup>a</sup>

Transfection	<i>Cis</i> -splicing <sup>b</sup>	<i>Trans</i> -splicing	Percentage
T1	3.7	-	
PTM3	-	-	
PTM5	-		
T1+PTM1	3.9	0.075	1.9%
T1+PTM3	4.1	0.088	2.2%
T1+PTM5	4.9	0.32	6.5%

<sup>a</sup>One representative experiment of 5 similar experiments is shown

<sup>b</sup>Numbers are in nanogram and depict the calculated amounts of DNA

To compare the specificity of *trans*-splicing between PTMs 1, 3 and 5, a non-specific target placZ-T4 containing mini-intron 9 of the CFTR gene was used.  $\beta$ -gal activity was not significantly increased over basal levels by transfection with pLacZ-T4 or each one of the PTMs alone. Co-transfection of the non-specific target with PTMs 1, 3 and 5 showed a decrease in  $\beta$ -gal activity correlated with changes in their binding domains. With PTM1 the non-specific *trans*-splicing was ~ 12% of specific *trans*-splicing between CF-Target and CF-PTM14. The PTM with the longest binding domain represented by PTM5 restored only ~ 6% the level of  $\beta$ -gal activity compared to that obtained between specific PTM and target.

To achieve protein restoration in COL17A1 harboring the 4003delTC mutation the complete C-terminus 3' of the mutation has to be incorporated into a PTM and *trans*-spliced into the mutant pre-mRNA by the spliceosome. To evaluate if this can be achieved, a COL17A1 mini-gene construct spanning exon 51, intron 51 and exon 52 including the addition of a FLAG-sequence at the 3' end (T2; Figure 2B) was transfected into 293T cells. To demonstrate the functionality of the mini-gene target, the *cis*-spliced mRNA derived from this construct was analyzed by RT-PCR and sequenced showing correct length of 568 bp (Figure 5A; upper panel). A series of PTMs were constructed based upon the LacZ PTMs described above, incorporating their target binding and *trans*-splicing domains but replacing the 3' lacZ exon by the cDNA sequence of COL17A1 exons 52 through 56. These PTMs named PTM2, PTM4 and PTM6 (Figure 2D) were transfected into 293T cells. No *trans*-spliced

product was detected by RT-PCR reaction using primers Ex51-1F and the exon 53 specific reverse primer KI-53-1R. However, co-transfection of the Col17A1 mini-gene target (T2) and either PTM 2, 4 or 6 followed by RT-PCR analysis indicated accurate *trans*-splicing producing the expected 574 bp fragment (Figure 5A; lower panel). Therefore, *trans*-splicing produces a RNA spanning from exon 51 to exon 56, replacing exon 52 and the attached FLAG sequence of the mini-gene target pre-mRNA. Sequence analysis showed the accuracy of the *trans*-splicing between the target pre-mRNA and the PTM. The possibility of DNA-recombination events was analyzed by PCR using primers Ex51-1F and KI-53-1R. No product was obtained eliminating the possibility of DNA-recombination events.

To evaluate if the keratinocyte-specific environment allows for *trans*-splicing to occur, the LacZ repair system was used in human keratinocytes. First LacZ-T1 or PTM5 alone were transfected into human keratinocytes which did not increase the level of  $\beta$ -gal activity beyond the levels measured in mock transfected keratinocytes.  $\beta$ -gal protein quantification produced a ~100 fold increase in  $\beta$ -gal activity over background due to mRNA repair by *trans*-splicing PTM5 pre-mRNA into LacZ-T1 pre-mRNA (Figure 6A; I). *Cis*-splicing of the target was detected by RT-PCR analysis of total RNA using primers Lac9F and KI-3R (Figure 6A; II, left panel). Primer pair Lac9F and KI-5R were utilized for analysis of *trans*-splicing (Figure 6A; II, right panel).

*Trans*-splicing in an immortalized Col17A1 deficient KC cell-line. Transfection of either LacZ-T1 or PTM5 alone produced no  $\beta$ -gal activity, nor positively stained cells in cell culture. Co-transfection of LacZ-T1 and PTM5 produced significant levels of  $\beta$ -gal activity (295 U/mg protein) (Figure 6B; I). In this cell type *cis*- and *trans*-splicing was detected using primer Lac9F and KI-3R (*cis*) or Lac9F and KI-5R (*trans*) (Figure 6B; II). In addition  $\beta$ -gal positive cells could be detected when LacZ-T1 and PTM5 were co-transfected in the immortalized GABEB cell line (Figure 4, lowest panel).

In both primary keratinocytes and the GABEB cell-line DNA, recombination events were ruled out by PCR analysis as described above. Additional



sequence analysis for both cell types showed accurate *trans*-splicing, with replacement of the stop codon containing exon.

The detection strategy for endogenous *trans*-splicing of the Col17A1 pre-mRNA in HaCatKC cells is shown in Figure 7. The pre-*trans*-splicing molecule (PTM5) which consists of a Col17A1 binding domain 51, spacer element, branch point (BP) and polypyrimidine tract (PPT) followed by a functional part of  $\beta$ -galactosidase lacZ 3' exon cloned into pcDNA3.1(-) is depicted. This construct was transfected into HaCat cells. Pre-mRNA resulted in correct endogenously *trans*-spliced product of a genomic fragment spanning exon 1-51 and LacZ 3' exon confirmed by semi-nested RT-PCR with primer 51-1F, lac6R and lac4R. Figure 8A depicts the sequence of correct endogenously *trans*-spliced splice junction of genomic fragment exon 51 with lacZ 3' exon and confirmation with restriction enzyme digest of 226bp RT-PCR product with MseI resulting in two fragments of 168bp and 58bp. (B).

## 15 7. EXAMPLE: TRANS-SPLICING OF THE PLECTIN TARGET PRE-mRNA

The subsection below describes experiments designed to mediate a *trans*-splicing reaction between a PTM and a plectin pre-mRNA molecule using 5' *trans*-splicing.

### 7.1 MATERIALS AND METHODS

20 Isolation and *in-vitro* culture of keratinocytes. Human keratinocytes are isolated from skin samples after skin biopsy, incubated with dispase at 4°C overnight and then trypsinized to obtain a single cell suspension. Cells cultured in KGM keratinocyte medium (BioWhittaker, Vervier, Belgium) at 0,15 mM Ca<sup>2+</sup>.

Cells and cell-lines. Patient keratinocytes from EBS-MD patients are collected by biopsies under local anesthesia, prepared using trypsin, expanded and frozen at different passage numbers in liquid nitrogen. Those keratinocytes with the plectin genetic background are immortalized using HPV16 E6 and HPV7 under the control of an actin promoter (provided by H. Lochmuller, Institute of Biochemistry-Genecenter, LMU, Munich, Germany).

30 Organotypic culture. Cadaver skin is obtained from a skin bank. The skin is tested to determine that the skin is HIV- and Hepatitis-B negative.

Cryopreserved skin is subjected to rapid freeze-thaw cycles in liquid nitrogen to devitalize the cells, washed in sterile PBS and incubated at 37°C in sterile PBS with antibiotics. Epidermis is removed. The acellular dermis is cut into pieces and each piece is placed into a tissue culture dish papillary side up. Transiently PTM-  
5 transfected plectin-deficient keratinocytes are placed on the dermis and grown submerged for one week which yielded a three- to five-cell layer. The skin composite is then lifted to the air-liquid surface, and grown for various periods of times and then analyzed.

Northern blotting. Cultured cells are trypsinized, lysed and RNA is  
10 isolated using anion-exchange columns (Qiagen, Hilden, Germany). Isolated RNA is electrophoresed and transferred to a nylon-membrane. The membrane is probed with <sup>32</sup>P-labeled cDNA fragments. The blots are washed and specific bands are detected by exposure to X-ray films. Probes are made using primers designed according to published sequences. After RT-PCR the fragments are subcloned into a pUC18  
15 plasmid and amplified according to standard procedures.

Immunofluorescence. Cultured keratinocytes are fixed with 3% paraformaldehyde. A plectin specific first step antibody (5B3, kindly provided by G. Wiche, Vienna, Austria) and a FITC-labeled secondary antibody is then applied to the sample. After a washing step the respective anti mouse-FITC labeled and anti-rat-  
20 Rhodamine labeled second step antibodies are applied. Slides are mounted and immunofluorescence is detected using a Zeiss microscope. The epidermis from organotypic culture will be snap-frozen and cut with a cryostat.

Western Blot analysis. Confluent cells are washed with PBS and scraped off the plate. Cell pellets are lysed in 50 mM Tris-HCl pH 7.5, 150 mM  
25 NaCl, 1% (v/v) Triton-X 100, 0.1% (w/v) SDS, 0.5 mM EDTA, 10 µM leupeptin, 100 µM phenylmethylsulfonylfluoride, 100 µM DTT. The epidermis from organotypic culture is lysed directly. 20 µg protein of control and test KC are loaded on a 5% SDS Polyacrylamide Gel. Following electrophoresis, proteins are transferred to nitrocellulose (Hybond C pure; Amersham Pharmacia Biotech, Little Chalfont, UK) in  
30 48 mM Tris-HCl, 39 mM Glycine, 20% (v/v) MeOH, 0.037% (w/v) SDS. The primary monoclonal antibody 5B3-is diluted 1:3 in blocking buffer (200 mM Tris-HCl

pH 7.6, 137 mM NaCl, 0.2% (w/v) I-Block, 0.1% (v/v) Tween 20). Immunodetection is monitored with the Western-Star™ Chemiluminescent Detection System (Tropix Inc., Bedford, MA, USA) following the manufacturer's instructions.

5                    Primers: PLEC-FN: 5' GGG AGC TGG TGC TGC TGC TGC TTC 3'  
                          PLEC-FM: 5' GGG AGC TGG TGC TGC TGC TGC TGC  
                          3'  
                          PLEC-R: 5' CTC TCA AAC TCG CTG CGG AGC TGC 3'

Cloning of the Exon 9 to Exon 10 region from plectin gene. The DNA  
 10    sequence of the plectin gene spanning exon 9 to exon 10 is amplified by using exon 9  
      upstream and exon 10 downstream primers. For a directional cloning of the fragment  
      restriction sites are added to the primers. The amplified DNA fragment was cloned  
      into a pGEM-3Zf(+) vector (Promega, Madison, USA). The region of exon 9/intron  
      9/exon 10 is sequenced to affirm the correct sequence. Also the genomic exon 9 to 10  
 15    region from the EBS-MD patient is cloned according to this protocol.

Construction of LacZ vectors and PTM's for *trans*-splicing mediated  
gene repair. To select for the best binding requirements in intron 9 of the plectin gene  
      artificial chimeric LacZ targets are constructed (LacZ-T3+T4; Figure 10) consisting  
      of: 5' fragment (5'-exon 1-1788bp) of the LacZ coding sequence with an insertion of  
 20    two in-frame stop codons at the 3' end (1761-1762), intron 9 of the plectin gene  
      (PLEC1), and the 3'-exon of-LacZ (1789-3170 bp) (= LacZ-T3); LacZ-T4: 5' fragment  
      (5' exon 1-1788bp) of the LacZ coding sequence, intron 9 of plectin gene (PLEC1),  
      and the 3'exon of LacZ (1789-3170 bp). In addition, repair molecules are constructed,  
      which are referred to as pre-*trans*-splicing molecules, (Lac-PTM3+4; Figure 11)  
 25    LacZ-PTM-3: Binding domain complimentary to intron 9 of PLEC1, a spacer and  
      very strong 5' splice site elements, followed by the 5' fragment of LacZ (1-1788bp)  
      (=PTM-3). PTM-4: Random non intron 9 binding domain followed by the 5' fragment  
      of LacZ (1-1788bp).

Construction of the PTM's is performed according to Puttaraju *et al.*, (Mol. Therapy, 2001, 4:105-114) using 5' splice site elements, a spacer region and a binding domain (BD) complementary to the intron 9 sequence at the 5' end of the intron to block *cis*-splicing. Exons 1 through 9 are amplified from cDNA using an exon 1 forward- and an exon 9 reverse-primer. The 5' PTM domain is attached to the exon fragment using restriction enzymes and ligation PCR technique. For *in-vitro* studies the PTM's are cloned into a vector containing SP6/T7 promoters (pGEM, pBS) for *in vitro* RNA synthesis. Furthermore, the PTM's are cloned into a mammalian expression vector (pcDNA 3.1, pcDNA 3.1/His/lacZ,) for *in vivo* transfection studies in human keratinocytes.

*In vitro* preparation of RNA. RNA is transcribed using the T7 and/or SP6 promoters on the pGEM-3Zf (+). For the synthesis, a T7/SP6 RNA synthesis kit (Promega) is used. 0.5 to 1 µg of template RNA is added to the transcription buffer and a nucleotide mixture (10 mM each). After 60 min. at 30°C RNase free DNase I is added to remove template DNA to avoid later interference of template DNA. The reaction is followed by gel purification using 4-8% PAGE to obtain RNA of homogeneous size. After overnight elution the RNA is precipitated.

*In vitro* splicing and trans-splicing using HeLa extracts. *In vitro* synthesized and gel purified PTM-RNA and target pre-mRNA is annealed after denaturing at 95-98°C followed by a slow cooling to 30-34°C. 4 µl of annealed RNA complex, 1x splice buffer and 4 µl of HeLa nuclear extract (Promega) in a final volume of 12.5 µl is incubated at 30°C for the time indicated. The reaction is stopped by adding an equal volume of high salt buffer. Nucleic acids is purified by phenol:chloroform extraction followed by ethanol precipitation. β-globin pre-mRNA was used as a positive control.

Reverse transcription (RT) PCR. RT-PCR is performed using *rTth* (Perkin Elmer) polymerase. Each reaction contains approximately 10 ng of the spliced RNA or 1-2 µg of total RNA. Enzyme buffer, 2.5 mM dNTP's, 10 pM 3' and 5' specific primer and 5U of enzyme are added to a reaction volume of 30 µl. RT-reaction is performed at 60°C for 45 min. Resulting cDNA is amplified by PCR using specific a specific exon primer.

Sequencing of RT-PCR products. The *trans*-spliced RT-PCR products are reamplified using a specific nested primer and the Perkin Elmer sequencing kit for cycle sequencing using dye-termination mix, 3-10 pmol/ $\mu$ l primer and 360 ng-1.5  $\mu$ g DNA. After cycle sequencing the reaction is precipitated with ethanol to remove  
5 unincorporated nucleotides and to reduce salt concentration. The pellet is dissolved in 25  $\mu$ l TSR (Template suppression reagent) followed by a 2-3 min. denaturation at 95°C. The sequencing reactions are analyzed using an ABI Prism 310 Sequencer (Perkin Elmer, Foster City, CA).

Transfection and cotransfection of target and PTM's into keratinocytes.

10 Keratinocytes are grown as described above. Cells are transfected with PTM's and target constructs for measuring *cis*- and *trans*-splicing efficiencies using lipofectamine following the manufacturer's protocol. Since transfection efficiency is crucial to these experiments a number of different liposomal transfection reagents have been evaluated. Fugene 6 (Roche Diagnostics, Mannheim, Germany) yields significantly  
15 improved transfection efficiency in KC (data not shown). In addition, electroporation is employed to further improve on transfection efficiency.

Construction of a cDNA library and 3'RACE.

3'RACE. Because of the known sequence of exon 9 it is possible to clone each exon 9 containing mRNA by 3'RACE (Volloch, V *et al.*, 1994, *Nucl Acid*  
20 *Res* 22:2507-2511). To generate 3' end-cDNA clones, reverse transcription (primer extension) is carried out to generate first-strand products. Amplification is achieved using a forward primer specific for exon 9 and an oligo-dT reverse primer to form the second strand of cDNA. Then PCR fragments are cloned and sequenced.

cDNA library. First strand cDNA is synthesized using an oligo-dT  
25 primer and M-MLV reverse transcriptase. 2-5  $\mu$ g of polyadenylated RNA is heated for 65°C for 5 min and chilled on ice. RT-buffer, 8mM dNTPs, 2 $\mu$ g oligo-dT primer, 25 $\mu$  RNasin and 200 $\mu$  M-MLV RT is added and incubated for 1 h at 37°C followed by a RNase H digestion. Excess primer is removed using spin filters. An aliquot of the cDNA is amplified using a nested exon 9 specific primer and oligo dT primer.  
30 Obtained products are flushed using Klenow enzyme or T4 DNA polymerase and cloned for sequence analysis.

## 7.2 RESULTS

Trans-splicing in a LacZ system. For gene correction of the plectin 1287ins3 mutation, a 5' lacZ model system is used. The corrected fragment for 5' *trans*-splicing is only 1356 bp long as opposed to 12833 bp for 3' *trans*-splicing (Figure 9).

Accurate *trans*-splicing between LacZ-T3 and LacZ-PTM3 leads to the production of a functional mRNA that produces into significant levels of  $\beta$ -galactosidase activity in the LacZ system since the stop codon introduced in the 5' LacZ fragment is eliminated.  $\beta$ -galactosidase activity is not expected when PTM or target constructs are transfected alone.

Based on the results obtained when the LacZ-T3 and LacZ PTM3 are co-transfected, appropriate controls for transfection and splicing efficiency using a construct with plectin intron 9 inserted into the LacZ reading frame is transfected (LacZ-T4) into cells (Figure 10). This transfection will yield a functional  $\beta$ -galactosidase without co-transfection upon *cis*-splicing. Furthermore, comparison of targeted vs. non-targeted (non-targeted PTM contains random sequence in place of plectin binding domain; LacZ-PTM4; Figure 11) *trans*-splicing will indicate the specificity at the RNA level (RT-PCR analysis) as well as at the protein level ( $\beta$ -galactosidase activity). Variation in the length of the binding domain, inclusion of nonspecific sequences and other modifications in the *trans*-splicing domain binding sequences will provide important information on the most efficient PTM sequences.

Trans-splicing in cell culture. The efficiency of PTM-induced *trans*-splicing versus *cis*-splicing is evaluated in a nonselected transient transfection assay. 293T cells are transfected with a mammalian expression vector containing a plectin PTM-5 (Figure 12) containing the binding domain found to be spliced most efficiently and harboring exons 1-9 including the 1287ins3 mutation (Figure 12, PLEC-PTM-5). Total RNA is isolated 48 h post transfection and analyzed by RT-PCR using primers. The amplified product is sequenced, to confirm that PTM-driven *trans*-splicing occurs in these cells at the predicted splice sites. *Cis*-splicing is detected by primers PLEC-R and PLEC-FN. *Trans*-splicing is detected by primer pair PLEC-R and PLEC-FM.

*Trans*-splicing should be detected in a 50 ng total RNA sample. The *cis*-spliced products can be discriminated in the same RNA pool from *trans*-spliced products by a 3 bp length difference. No *trans*-splicing is expected in cells transfected with either target alone or control plasmids alone. The efficiency of PTM-mediated RNA *trans*-splicing versus *cis*-splicing is evaluated by a semi-quantitative RT-PCR with increasing amounts of total-RNA using *cis*- and *trans*-specific primers (see above). To exclude the possibility of recombination between the target and PTM-plasmids, total DNA was isolated from 293T cells transfected with PLEC-PTM-5 plasmids. PCR is performed with the same primers (PLEC-R and PLEC-FM) used for reverse transcription PCR to detect *trans*-splicing between the endogenous plectin gene and PLEC-PTM-5.

Evaluation of nonspecific *trans*-splicing by 3' RACE and cDNA-library construction in 293T cells. To determine the specificity of PTM's, *i.e.*, whether they are *trans*-spliced into other endogenous RNAs, 3' RACE is used to amplify the sequence of all *trans*-spliced reaction sites. Specifically, reverse transcription will be initiated from an oligo-dT primer. Resulting cDNAs are amplified using a nested exon 9 primer and an oligo dT primer. The amplified products are cloned and sequenced. In addition, cDNA libraries can be constructed from transfected cells to detect illegitimate *trans*-splicing using a standard dT approach (Sambrook, J *et al.*, 1989 Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). Individual clones will be checked for sequences specific to the PLEC-PTM-3 construct.

*Trans*-splicing in Keratinocyte cell-culture. Gene-correction in keratinocytes from plectin-deficient patients by transient transfection. Spliceosome mediated RNA *trans*-splicing PTMs are designed that are capable of repairing mutated plectin pre-mRNA in patient cells. Since the amount of endogenous plectin mRNA is not reduced in these patient cells (Bauer *et al.*, 2001, *Am J. Pathol* 158:617-625) there should be no reduction of plectin pre-mRNA containing the required intron 9 pre-mRNA sequences. Based upon information obtained from preliminary experiments, new PTMs are constructed that contain sequences encoding the complete 5' end of plectin from exons 1 through 9 (PLEC-PTM-6). These constructs are tested

by RT-PCR for RNA repair in plectin deficient cells (Figure 13). Efficiency of *trans*-splicing versus *cis*-splicing are assayed using *cis*- and *trans*-specific primers. RT-PCR products are sequenced to verify proper splicing between PLEC-PTM-6 and target. PCR of the total cellular DNA (with no Reverse Transcription step) is analyzed to rule out homologous recombination. The specificity of each PTM in *trans*-splicing to target versus non-target is examined by performing 3' RACE followed by the cloning and sequencing of a number of clones. PTM specificity is examined for PLEC-PTM-6 and its derivatives.

Inclusion of a safety domain into the binding domain is known to decrease nonspecific *trans*-splicing, thus, a second type of plectin PTM is also developed, the plectin-safety-PTM. The binding domain of this safety PTM has complementarity to regions of the PTM's splice site (PPT and BP), and has insertions to form a stem structure, which is designed to block access of splicing factors to the PTM splice site. A portion of the PTM binding domain left as single-stranded initiates contact with a target pre-mRNA. Upon binding to the target through base-pairing, the safety is predicted to unwind exposing the splicing elements which are now ready for binding with splicing factors.

Gene-repair and restoration of protein function in 1287ins3-plectin-deficient keratinocytes from patients on protein level. After transfection of the improved PTM into patients' keratinocytes, expression of plectin is evaluated by immunofluorescence analysis and Western blotting.

Trans-splicing in an organotypic culture. A composite skin is cultured as described above. The expression vector containing the improved PTM as determined above is used in these experiments. The growing composite skin equivalent is analyzed at time points day 1-5 after being lifted to the air by immunofluorescence for correct expression of plectin.

#### 8. EXAMPLE: TRANS-SPLICING TO THE ENDOGENOUS COL7A1 GENE

The results described below demonstrate the feasibility of using *trans*-splicing to repair or correct the endogenous the COL7A1 and COL17A1 gene mutated in epidermolysis bullosa (EB).



As depicted in Figure 14A, PTM6 consists of a Col17A1 binding domain (intron 51), spacer element, branch point (BP) and poly pyrimidine tract (PPT) followed by exon 52-56 cloned into pcDNA3.1(-). This construct was transiently transfected into GABEB cells harboring the 4003 del TC mutation. Pre-mRNA splicing in GABEB cells resulted in a correct endogenously *trans*-spliced product of a genomic fragment spanning exon 1-56 which was confirmed by semi nested RT-PCR. RNA was extracted from PTM6 transfected GABEB cells and semi-nested RT-PCR was performed with BPAG2-primer 51-1F, 53-1R and 52-1R. DNA sequencing of the expected 323bp fragment was performed, which revealed both the mutant and *trans*-spliced corrected alleles (Figure 14B).

To quantify wildtype vs. mutant DNA in the 323bp fragment, the fragment was cloned into a TOPO vector. 100 clones were analysed by colony PCR and subsequent NlaIII digest, which detects the 4003 del TC mutation in the COL17A1 gene. A given digest profile of 4 different possibilities and fragment sizes are shown. Quantification of TOPO clones revealed *trans*-splicing efficiency of almost 50% (Figure 14C, 14D, 14E). Expression of the type XVII collagen protein in the GABEB cell line due to correct *trans*-splicing of PTM6 was demonstrated by immunofluorescence (IF) of transfected cells (Figure 15), which was not present in control cells.

The design of specific PTMs for each target gene should be modified to reach optimal *trans*-splicing efficiencies in the COL7A1 gene (Figure 17 and 18). Figure 17 depicts a  $\beta$ -gal assay of a co-transfection of Col7 target T1 and PTM 8, 9 and 10 in 293T cells with Lipofectamine. In addition,  $\beta$ -gal staining of Col7 PTM transfected human HEK 293T cells shows correct *trans*-splicing events. (Figure 18)

The results show that endogenous *trans*-splicing is detected in keratinocytes derived from patients suffering from epidermolysis bullosa. From earlier studies it was shown that the efficiency of *trans*-splicing in a PTM and target plasmid co- transfection assay was 24% when correcting for the transfection efficiency (Dallinger G et al., 2003, Exp Dermatol. Feb;12(1):37-46). In the model

used in the current studies (endogenous *trans*-splicing with a correcting 3' end of COL17A1) the efficiency of trans-splicing was found to be roughly 50%, though the absolute number of trans-splicing events is likely to be lower in the endogenous system.

5                   The present invention is not to be limited in scope by the specific  
embodiments described herein. Indeed, various modifications of the invention in  
addition to those described herein will become apparent to those skilled in the art from  
the foregoing description and accompanying Figures. Such modifications are intended  
to fall within the scope of the appended claims. Various references are cited herein,  
10   the disclosure of which are incorporated by reference in their entireties.

WE CLAIM:

1. A cell of the skin comprising a nucleic acid molecule wherein said nucleic acid molecule comprises:

- 5                                   a)     one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b)     a 3' splice region comprising a branch point and a 3' splice acceptor site;
- 10                                  c)     a spacer region that separates the 3' splice region from the target binding domain; and
- d)     a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

                                     wherein said nucleic acid molecule is recognized by nuclear splicing components  
15     within the cell of the skin.

2. A cell of the skin comprising a nucleic acid molecule wherein said nucleic acid molecule comprises:

- a)     one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- 20                                   b)     a 3' splice acceptor site;
- c)     a spacer region that separates the 3' splice region from the target binding domain; and
- 25                                  d)     a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

                                     wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell of the skin.

30                                  3 A cell of the skin comprising a nucleic acid molecule wherein said nucleic acid molecule comprises:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 5' splice site;
- 5 c) a spacer region that separates the 5' splice site from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components  
10 within the cell of the skin.

4. The cell of claim 1 wherein the nucleic acid molecule further comprises a 5' donor site.

15 5. The cell of claim 1 wherein the 3' splice region further comprises a pyrimidine tract.

6. The cell of claim 1, 2 or 3 wherein said nucleic acid molecule further comprises a safety sequence comprising one or more complementary  
20 sequences that bind to one or both sides of the 5' splice site.

7. The cell of Claim 1, 2 or 3 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice region.  
25

8. The cell of Claim 1 wherein the binding of the nucleic acid molecule to the target pre-mRNA is mediated by complementary, triple helix formation, or protein-nucleic acid interaction.

30

9. The cell of Claim 1 wherein the nucleotide sequences to be *trans*-spliced to the target pre mRNA encodes a polypeptide expressed within the cell of the skin.

5                   10. The cell of claim 9 wherein the polypeptide is a keratinocyte specific polypeptide.

11. The cell of claim 9 wherein the polypeptide is a melanocyte specific polypeptide.

10

12. The cell of Claim 9 wherein the polypeptide is selected from the group consisting of a plectin, type VII collagen, type XVII collagen, and laminin polypeptide.

15

13. The cell of claim 1 wherein said cell is a cancer cell of the skin.

14. The cell of claim 10 wherein said cell is a melanoma or basal cell carcinoma cell.

20

15. The cell of claim 1 wherein said cell is selected from the group consisting of a keratinocyte, melanocyte and dermal papilla cell.

16. A cell of the skin comprising a recombinant vector wherein said vector expresses a nucleic acid molecule comprising:

25

a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;

b) a 3' splice region comprising a branch point and a 3' splice acceptor site;

30

c) a spacer region that separates the 3' splice region from the target binding domain; and

- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell of the skin.

5

17. A cell of the skin comprising a recombinant vector wherein said vector expresses a nucleic acid molecule comprising:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 3' splice acceptor site;
- c) a spacer region that separates the 3' splice region from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

10

15

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell of the skin.

18. A cell of the skin comprising a recombinant vector wherein said

vector expresses a nucleic acid molecule comprising:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 5' splice site;
- c) a spacer region that separates the 5' splice site from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

25

30

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell of the skin.

19. The cell of claim 16 wherein the nucleic acid molecule further comprises a 5' donor site.

20. The cell of claim 16 wherein the 3' splice region further comprises  
5 a pyrimidine tract.

21. The cell of Claim 16, 17 or 18 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice region.  
10

22. A method of producing a chimeric RNA molecule in a cell of the skin comprising:

contacting a target pre-mRNA expressed in the cell of the skin with a nucleic acid molecule recognized by nuclear splicing components  
15 wherein said nucleic acid molecule comprises:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 3' splice region comprising a branch point and a 3' splice acceptor site;  
20
- c) a spacer region that separates the 3' splice region from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

25 under conditions in which a portion of the nucleic acid molecule is *trans*-spliced to a portion of the target pre-mRNA to form a chimeric RNA within the cell of the skin.

23. A method of producing a chimeric RNA molecule in a cell of the  
30 skin comprising:

contacting a target pre-mRNA expressed in the cell of the skin with a nucleic acid molecule recognized by nuclear splicing components wherein said nucleic acid molecule comprises:

- 5 a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 3' splice acceptor site;
- c) a spacer region that separates the 3' splice region from the target binding domain; and
- 10 d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA; under conditions in which a portion of the nucleic acid molecule is *trans*-spliced to a portion of the target pre-mRNA to form a chimeric RNA within the cell of the skin.

15

24. A method of producing a chimeric RNA molecule in a cell of the skin comprising:

contacting a target pre-mRNA expressed within the cell with a nucleic acid molecule recognized by nuclear splicing components wherein said

20 nucleic acid molecule comprises:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within the cell of the skin;
- b) a 5' splice site;
- 25 c) a spacer region that separates the 5' splice site from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components

30 within the cell.



25. The method of claim 22 wherein the nucleic acid molecule further comprises a 5' donor site.

26. The method of claim 22 wherein the 3' splice region further  
5 comprises a pyrimidine tract.

27. The method of claim 22, 23, or 24 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice region.  
10

28. The method of Claim 22 wherein the nucleotide sequences to be *trans*-spliced to the target pre-mRNA encodes a polypeptide expressed within the cell of the skin.

29. The method of claim 28 wherein the polypeptide is a keratinocyte specific polypeptide.  
15

30. The method of claim 28 wherein the polypeptide is a melanocyte specific polypeptide.  
20

31. The method of Claim 28 wherein the polypeptide expressed within the cell of the skin is selected from the group consisting of a plectin, type VII collagen, type XVII collagen, and laminin polypeptide.

32. The method of claim 22 wherein said cell of the skin is a cancer cell.  
25

33. The method of claim 32 wherein said cell is a melanoma or basal cell carcinoma cell.  
30

34. The method of claim 32 wherein the nucleotide sequence to be trans-spliced to the target pre-mRNA encodes a polypeptide that is toxic or of therapeutic value to said cell.

5 35. The method of claim 22 wherein said cell is selected from the group consisting of a keratinocyte, melanocyte and dermal papilla cell.

36. A nucleic acid molecule comprising:

- 10 a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- b) a 3' splice region comprising a branch point and a 3' splice acceptor site;
- 15 c) a spacer region that separates the 3' splice region from the target binding domain;and
- d) a nucleotide sequence to be trans-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components  
20 within the cell.

37. A nucleic acid molecule comprising:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- 25 b) a 3' splice acceptor site;
- c) a spacer region that separates the 3' splice region from the target binding domain;and
- d) a nucleotide sequence to be trans-spliced to the target pre-mRNA;
- 30

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

38. A nucleic acid molecule comprising :

- 5                   a)     one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- b)     a 5' splice site;
- c)     a spacer region that separates the 5' splice site from the target binding domain; and
- 10                  d)     a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

15

39. The nucleic acid molecule of claim 36 wherein the nucleic acid molecule further comprises a 5' donor site.

40. The nucleic acid molecule of claim 36 wherein the 3' splice region

20 further comprises a pyrimidine tract.

41. The nucleic acid molecule of claim 36, 37 or 38 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice

25 region.

42. The nucleic acid molecule of claim 36 wherein the binding of the nucleic acid molecule to the target pre-mRNA is mediated by complementary, triple helix formation, or protein-nucleic acid interaction.

30

43. The nucleic acid molecule of claim 36 wherein the nucleotide sequences to be trans-spliced to the target pre mRNA encodes a polypeptide expressed within a cell of the skin.

5                   44. The nucleic acid molecule of claim 43 wherein the polypeptide is a keratinocyte specific polypeptide.

45. The nucleic acid molecule of claim 40 wherein the polypeptide is a melanocyte specific polypeptide.

10

46. The nucleic acid molecule of Claim 43 wherein the polypeptide expressed within the cell of the skin is selected from the group consisting of a plectin, type VII collagen, type XVII collagen, and laminin polypeptide.

15

47. The nucleic acid molecule of claim 36 wherein the nucleotide sequence to be *trans*-spliced to the target pre-mRNA encodes a polypeptide that is toxic or of therapeutic value to said cell.

20

48. A eukaryotic expression vector wherein said vector expresses a nucleic acid molecule comprising:

25

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- b) a 3' splice region comprising a branch point and a 3' splice acceptor site;
- c) a spacer region that separates the 3' splice region from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the

30

cell of the skin.

49. A eukaryotic expression vector wherein said vector expresses a nucleic acid molecule comprising:

- 5                   a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- b) a 3' splice acceptor site;
- c) a spacer region that separates the 3' splice region from the target binding domain; and
- 10               d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

15               50. A eukaryotic expression vector wherein said vector expresses a nucleic acid molecule comprising:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin;
- 20               b) a 5' splice site;
- c) a spacer region that separates the 5' splice site from the target binding domain; and
- d) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

25       wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

51. The vector of claim 48 wherein the nucleic acid molecule further comprises a 5' donor site.

30

52. The vector of claim 48 wherein the nucleic acid molecule further comprises a pyrimidine tract.

53. The vector of claim 48, 49 or 50 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice region.

54. The vector of claim 48, 49 or 50 wherein said vector is a viral vector.

10

55. The vector of claim 44, 43 or 44 wherein expression of the nucleic acid molecule is controlled by a skin cell specific promoter.

56. A composition comprising a physiologically acceptable carrier and a nucleic acid molecule according to any of claims 36-47.

57. The composition of claim 56 wherein said composition is applied to the skin.

58. A method for correcting a genetic defect in a subject comprising administering to said subject a nucleic acid molecule comprising:

a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin wherein said pre-mRNA is encoded by a gene containing a genetic defect; and

25 b) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA;

wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

30

59. A method for imaging gene expression in a cell of the skin comprising administering to said subject a nucleic acid molecule comprising:

- a) one or more target binding domains that target binding of the nucleic acid molecule to a pre-mRNA expressed within a cell of the skin wherein said pre-mRNA is encoded by a gene containing a genetic defect; and
  - b) a nucleotide sequence to be *trans*-spliced to the target pre-mRNA wherein said nucleotide sequence encodes a reporter molecule;
- 10 wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell.

# FIGURE 1






Figure 1. Schematic representation of different SMaRT reactions. (a) *Trans-splicing* reactions between the target 5' splice site and PTMs 3' splice site; (b) *Trans-splicing* reactions between the target 3' splice site and PTMs 5' splice site and (c) Replacement of internal exon by double *trans-splicing* reaction in which the PTM carry both 3' and 5' splice sites. BD, binding domain; BP, branchpoint sequence; PPT, polypyrimidine tract and ss, splice sites.



# FIGURE 2A

## 1) BPAG2 Target 1 (LacZ-T1)



**2) BPAG2 Target 2 (T2)****FIGURE 2B**




FIGURE 2C




FIGURE 2D





FIGURE 3A-B

**FIGURE 3C**






FIGURE 4

A



**B**



**FIGURE 5A-B**







FIGURE 6A

**FIGURE 6B**

**FIGURE 7**

Detection Strategy for  
Exogenous Trans-splicing in the  
Col17A1 pre-mRNA in Hela cells






FIGURE 8

Endogenous Transsplicing  
of Col17 pre-mRNA with PTM5 pre-mRNA

A)




B)




## FIGURE 9.

### 5' trans-splicing in a LacZ-model system for hereditary diseases



## FIGURE 10


Target LacZ-T3 (containing Intron 9) and LacZ-T4 used for optimizing trans-splicing and transfection conditions




## FIGURE 11

LacZ-PTM-3 (Intron 9 specific binding domain) and LacZ-PTM-4 (non specific binding domain) for establishing optimal trans-splicing conditions

*Lac-PTM3*




*Lac-PTM4*



## FIGURE 12

PLEC-PTM-5 for the introduction of the 1287ins3 mutation  
in 293T cells





### FIGURE 13

### PLEC-PTM-6 for the repair of the 1287ins3 mutation in plectin deficient patient cells

**PLEC-PTM-6**




FIGURE 14A

**Trans-splicing Strategy for Col17A1 Gene  
(GABEB/generalized atrophic benign epidermolysis  
bullosa)**






FIGURE 14B

# Semi-nested RT-PCR with BPAG2- primer 51-1F, 53-1R and 52-1R



## FIGURE 14C

## TOPO Cloning + Nla III digest



## FIGURE 14D

Sequencing of mutant and  
wildtype clones confirmed the  
correct *trans*-splicing of PTM6  
into GABEB cells





FIGURE 14E

# Analysis of 100 clones




## FIGURE 15

### Immunofluorescence of PTM6-transfected GABEB cells

GABEB  
non-transfected



GABEB  
PTM6 transfected, 3 days



## FIGURE 16A-B



**Trans-splicing strategy for COL7A1 gene  
(Dystrophic epidermolysis bullosa)**




FIGURE 17

$\beta$ -gal Assay of a Cotransfection of Col7 Target T1 and PTM 8, 9, 10 in 293T cells



## FIGURE 18

# Beta-gal staining of Col7 PTM transfected human 293T cells



left panel: (a) Target + PTM8, (c) Target + PTM9, (e) Target + PTM10;  
right panel: corresponding control PTM without Target.

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US03/22469

## A. CLASSIFICATION OF SUBJECT MATTER

 IPC(7) : A01N 47/40; C12N 5/08, 5/10, 15/63; C07H 21/02, 21/04; C12P 19/34  
 US CL : 435/91.3, 91.31, 320.1, 371, 455; 514/44; 538/23.1, 24.5  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/91.3, 91.31, 320.1, 371, 455; 514/44; 538/23.1, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

West, Dialog

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,280,978 B1 (MITCHELL et al) 28 August 2001m figures 8, 10, 16, 17, col. 1, 2, 12, 16, 19, 21, 23, 29, 30, claims 1-32.	1-59
Y	US 6,013,487 (MITCHELL et al) 11 January 2000, col. 1, 5, 6, example 5, col. 14-15, claims 1-34).	1-59
Y	US 5,872,241 (PYLE et al) 16 February 1999, col. 2-3, col. 10, line 62-col. 11, line 5.	1-59
Y	PUTTARAJU, M. et al. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nature Biotech. Vol. 17, pates 246-252, 1999. see entire document, esp. figure 1, Table 1, and figure 2, on pages 247-248.	1-59

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"g" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 OCTOBER 2003


Date of mailing of the international search report

31 OCT 2003

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer


 Valerie Bell-Hamilton

Telephone No. (703) 808-0196

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**